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ABSTRACT OF DISSERTATION
SEMISYNTHETIC AURONES: A FAMILY OF NEWLY
DISCOVERED TUBULIN INHIBITORS AS ANTINEOPLASTIC AGENTS
Aurones belong to an uncommon class of plant flavonoids that provide the bright
yellow coloration of some ornamental flowers and that possess a range of biological
activities. Structure-activity relationships (SAR) in the aurone pharmacophore identified
heterocyclic variants of the (Z)-2-benzylidene-6-hydroxybenzofuran-3(2H)-one scaffold
that possessed low nanomolar in vitro potency in cell proliferation assays using various
cancer cell lines, in vivo potency in prostate cancer PC-3 xenograft and zebrafish models,
selectivity for the colchicine-binding site on tubulin, and absence of appreciable toxicity.
Among biologically active analogs developed in the course of this dissertation work were
(Z)-2-((2-((1-ethyl-5-methoxy-1H-indol-3-yl)methylene)-3-oxo-2,3-dihydrobenzofuran-6
-yl)oxy)acetonitrile (5a) and (Z)-6-((2,6-dichlorobenzyl)oxy)-2-(pyridin-4-ylmethylene)
benzofuran-3(2H)-one (5r). These two aurones 5a and 5r inhibited in vitro PC-3 prostate
cancer cell proliferation with IC50 values below 100 nM. A xenograft study in nude mice
using 10 mg/kg of 5a for 18 days had no effect on mice weight, and aurone 5a did not
inhibit, as desired, the human ether-à-go-go-related (hERG) potassium channel. Cell cycle
arrest data, comparisons of the inhibition of cancer cell proliferation by aurones and known
antineoplastic agents, and in vitro inhibition of tubulin polymerization indicated that
aurone 5a disrupted tubulin dynamics. Based on a National Cancer Institute COMPARE
analysis, studies using computer-based molecular docking and liquid chromatographyelectrospray ionization-tandem mass spectrometry studies, aurone 5a targets the
colchicine-binding site on tubulin. In addition to solid tumors, aurones 5a and 5r strongly
inhibited in vitro a panel of human leukemia cancer cell lines and the in vivo myc-induced
T cell acute lymphoblastic leukemia (T-ALL) in a zebrafish model. In summary, aurones
possess a pharmacophore of considerable potential in the search for new antineoplastic
agents for the clinical treatment of human cancers.
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Chapter 1 Background and Introduction
Society’s cancer burden
Cancer is a collection of different diseases that are characterized by abnormal cell
proliferation and cell metastasis to other parts of the body. Due to the genomic instability
and heterogeneity of tumors, current treatments often fail to eradicate all malignant cancer
cells and thus set the stage for cancer relapse as well as metastasis leading to premature
death. According to the World Health Organization, cancer is the second leading cause of
death with an estimated 9.6 million deaths worldwide in 2018. The most common organs
that develop cancers and the organ-specific cancers causing deaths are shown in Figure 1.1
and Figure 1.2, respectively.
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Figure 1.1: Most common cancers in 2018 (source: World Health Organization)
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Although medical advances in cancer treatment have succeeded in extending
human lifetimes, cancer remains as a significant financial burden for society. The total
annual costs of cancer diagnosis and treatment in 2010 in the United States was estimated
at approximately $1.16 trillion1. The projected total cost of cancer care in 2020 is estimated
at $173 billion, a 39% increase compared with the costs in 20102. Cancer represent an
enormous burden to the patients, their families, and their societies, and efforts to treat these
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diseases represent an important, intellectually intriguing goal for science.
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Figure 1.2: Most common causes of cancer-related death in 2018 (source: World
Health Organization)
The development of cancer therapeutics
To reduce this cancer burden, the development of new therapeutics, including
traditional “small molecules” and inventive “large molecules” such as antibodies,
continuously evolved as we learned more about tumor molecular biology than we knew in
the past. The transition from traditional, nonspecific chemotherapeutics such as cellular
poisons modifying DNA to targeted therapies such as kinase inhibitors selectively affecting
2

signaling pathways in cancer cells represents a dramatic change. In addition, as our
understanding of cancer biology increases, we gained a capacity to design treatments
possessing specificity for cancer cells and avoiding significant side-effects on normal cells.
Even these modern-day approaches are not without problems because targeted inhibitors
are often effective during initial treatments but patients subsequently develop resistance to
them during their long-term use.
The development of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) for the treatment of EGFR mutant Non-Small Cell Lung Cancers
(NSCLCs) is an important example that showcases drug resistance and resistance-driven
drug development. The EGFR tyrosine kinase regulates cell growth and proliferation and
activating mutations drive NSCLC malignancy3. First generation EGFR TKIs gefitinib and
erlotinib as well as second generation irreversible TKIs, afatinib and dacomitinib, are
effective for about a year in most patients but then develop minimal effects due to a new
acquired ATP pocket “gatekeeper” point mutation T790M4. To address the resistance
caused by the mutant EGFR harboring T790M, third generation EGFR TKIs including
WZ40025 and CO16866 were developed to target T790M EGFR selectively and spare the
wild type EGFR as a means for reducing side-effects such as diarrhea and rash. The third
generation EGFR TKIs are irreversible inhibitors that covalently bind to ATP pocket
Cys797. Unfortunately, resistance to these third generation EGFR TKIs was found and
EGFR C797S was revealed as a leading mechanism of resistance7. Recently, a fourth
generation of EGFR TKIs were developed to target C797S/T790M EGFR mutant. One of
the examples is an allosteric EGFR inhibitor EAI045, in which binding to EGFR is distant
from the ATP-binding site8.
3

In addition to the success of “small-molecule” chemotherapeutics, antineoplastic
antibodies such as the immune checkpoint blockers achieved impressive results with
patients achieving a cancer-free state in some rare cases. However, only a small portion of
patients respond to cancer immunotherapies and the cost of immunotherapies at “$1 million
per patient”9 is probably unsustainable. Small-molecule therapeutics will continue to
enhance immunotherapies with respect to the resistance to cancer immunotherapies and
their cost. Continued efforts focused on discovering novel small molecules remains as a
worthy goal.

Microtubules and tubulin inhibitors

Microtubule structure
Microtubules are key components of the cellular cytoskeleton and perform
important functions in cellular processes including cell cycle, cell morphology,
intracellular transport and cell migration10. Microtubules are hollow, cylindrical polymeric
structures with a diameter of approximately 25 nm, and are assembled from 13
protofilaments per microtubule10. These protofilaments polymerize from alpha-tubulin and
beta-tubulin dimers in a head-to-tail fashion as shown in Figure 1.3. The αβ-tubulin
heterodimers are two 50-kDa proteins and show about 50% similarity.
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The polarity of microtubules is defined as (+)-and (-)ends 11 in which the (+)-end
is the one ringed with beta-tubulin and the (-)-end is the one ringed with alpha-tubulin
(Figure 1.3). Microtubules bind to microtubule-associated proteins that form the
microtubule-organizing center. The (-)-ends of microtubules are anchored to the
microtubule-organizing center whereas the (+)-ends are the dynamic locus for adding or
removing tubulin dimers11.

Figure 1.3: The four binding sites of tubulin inhibitors on tubulins and
microtubules. This figure is from Lu et al. Pharm Res. 2012, 29(11):2943-2971.

Importance of microtubule dynamics
One key feature of microtubules is their dynamic instability, meaning that
microtubules are constantly either growing or shortening in length by adding or removing
tubulin dimers12. Tubulins are guanosine triphosphate (GTP)-binding proteins although
the GTP in alpha-tubulin is neither hydrolyzed nor exchanged with guanosine diphosphate
5

(GDP). For beta-tubulins, the bound GTP is hydrolyzed to guanosine diphosphate (GDP)
after polymerization13. When the (+)-ends of microtubules are capped with GTP-bound
beta-tubulins, then these microtubules will grow. If beta-tubulin-bound GTP hydrolysis
faster than the rate of tubulin addition, the (+)-ends of microtubules are capped with GDPbound beta-tubulins and these microtubules depolymerize to shorten the length.
Apart from the GTP-GDP cycling, tubulins also undergo structural changes in the
microtubule assembly-disassembly process. Crystallography studies show that tubulins
dimers are in a “curved conformation” while tubulins after polymerization into
microtubules are in a “straight conformation”12,14. Structural changes that occur during
tubulin polymerization are within each alpha and beta-tubulin heterodimer and the interheterodimer interface. These reorientations are accompanied by structural rearrangements
within tubulin subdomains.
Structural changes within tubulin heterodimers occur in the presence and absence
of tubulin polymerization inhibitors. Colchicine is a well-established tubulin inhibitor
(Figure 1.4) that binds to a specific colchicine-binding site (Figure 1.3) lying at the
interface of alpha and beta-tubulin heterodimers. This site also accommodates chemically
diverse ligands such as ABT751, TN16 (Figure 1.4) and others (reviewed in reference15).
With or without colchicine occupying the colchicine-binding site, tubulin heterodimers are
in a curved conformation. However, the T7 loop that links helix H7 and helix H8 (i.e.,

6

Figure 1.4: Structurally diverse colchicine site binders: colchicine, ABT751, and
TN16.

helical designations in tubulin secondary structure nomenclature described in reference14)
in beta-tubulin flips into the colchicine-binding site during the conformational change from
curved to straight16. When the colchicine-binding site is occupied by a ligand, the
conformational change in the T7 loop cannot occur, and tubulins cannot transition to the
straight conformation. These circumstances inhibit tubulin polymerization16.
Tubulin polymerization is a critical part of tubulin dynamics, and tubulin inhibitors
that disrupt this process lead to fatal effects for cells. During the cell cycle, a cell forms a
mitotic spindle in which microtubules are the main components. During metaphase and
anaphase, chromosomes are quickly aligned and then segregated into daughter cells by
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mitotic spindle. Tubulin inhibitors disrupt this process and lead to cell cycle arrest at G2/M
phase and ultimately cell death17.
Examples of microtubule-targeting agents
Tubulin inhibitors function by disrupting microtubule dynamics, either by
inhibiting tubulin polymerization or by stabilizing microtubules. Over the years, many
tubulin inhibitors were identified and categorized into four classes according to the natural
products that target specific binding sites15: the laulimalide, taxane, Vinca alkaloid, and
colchicine sites (Figure 1.3). Colchicine binds to the colchicine-binding site at the interface
of tubulin heterodimers and Vinca alkaloids such as vinblastine bind to beta-tubulins.
These two classes of inhibitors both inhibit tubulin polymerization. Taxanes bind to
polymerized microtubules at the inner surface and stabilizes microtubules while
laulimalide stabilizes microtubules but binds to a different site of microtubules.
Taxanes are a structurally complex but valuable class of diterpenes, and important
representatives of this class include paclitaxel and docetaxel that are used in chemotherapy
for breast cancer and prostate cancer18. These compounds have poor water-solubility and
require polyethoxylated castor oil and ethanol for intravenous administration. Patients
develop resistance to taxanes due to the expression of ABC drug transporters19, which
decrease intracellular drug concentrations and reduces bioavailability. Another class of
tubulin-stabilizing agents are the Vinca alkaloids (i.e., vincristine, vinblastine, vindesine
and vinorelbine) that are isolated from the periwinkle plant, Catharanthus rosea, and are
the chronologically oldest of that microtubule-targeting agents. One of the fluorinated
vinorelbine analogs, vinflunine, is approved to treat bladder cancer, and vinblastine was
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used to treat a number of cancers including Hodgkin's lymphoma, non-small cell lung
cancer, bladder cancer, brain cancer, melanoma, and testicular cancer20.
Colchicine finds frequent use in the treatment of gout21, but its toxicity precludes
its use in cancer treatment. Although the literature describes a number of colchicine-site
binders as tubulin inhibitors19, none of these agents has yet gained FDA-approval for
cancer chemotherapy. One of the advantages of colchicine-site binders is that many of
these compounds are not substrates of P-glycoprotein (Pgp) drug efflux pumps19. Therefore,
resistance that plagues drugs such as those in the taxane class may be less of an issue for
colchicine-site binders. Combretastatin A-4 phosphate (CA4P) is a prodrug developed by
Oxigene to treat solid tumors19. CA4P is dephosphorylated in vivo to the active metabolite
CA4 that binds to the colchicine-binding site. Despite multiple clinical trials22, CA4P has
yet to receive regulatory approval.

Resistance to microtubule-targeting agents
Several

resistance

mechanisms

affect

microtubule-targeting

agents.

Overexpression of the MDR1 gene is a major setback for tubulin inhibitors including
taxanes and Vinca alkaloids. MDR1 encodes a Pgp drug efflux transporter that decreases
intracellular drug concentrations and reduces bioavailability. Secondly, because there are
at least 13 isotypes of tubulins, different compositions of microtubules show different
sensitivity to tubulin inhibitors. Overexpression of tubulin isotype βIII resulted in a slower
polymerization rate in comparison with other tubulin isotypes. This altered microtubule
dynamics lead to resistance to taxane and vinorelbine23,24. Thirdly, microtubule dynamics
9

are regulated by cellular proteins such as stathmin and microtubule associated protein 4.
Stathmin destabilizes microtubules while microtubule associated protein 4 promotes
microtubule formation. Overexpression of stathmin decreases paclitaxel sensitivity in
breast cancer and microtubule associated protein 4 overexpression reduces cytotoxicity of
Vinca alkaloids25,26. Overall, these resistance mechanisms warrant further efforts to
develop new tubulin inhibitors that may overcome these types of drug resistance.

Aurones
Aurones are a sub-class of naturally occurring flavonoids that feature a common
structural scaffold described as (Z)-2-benzylidenebenzofuran-3(2H)-one. The bright
yellow color of ornamental flowers such as the snapdragon (Antirrhinum majus) derives
from aurones. The biosynthesis of aurones involves the shikimate pathway leading first to
phenylalanine and hence to from p-coumaroyl CoA27. The addition of malonyl CoA
extends the p-coumaroyl to a chalcone, and the enzyme, aurone synthase , catalyzes the
conversion of chalcones, using hydroxylation and oxidative cyclization reactions, to
aurones (Figure 1.5)28,29. The main biological functions of aurones in plants are coloration
of flowers and fruits and defense against insects and viruses30.
Aurones are not as widely distributed in nature as other common flavonoids31,
which is probably the reason why they have received less attention in comparison to the
structurally similar and widely investigated flavones and isoflavones. Still, a number of
interesting biological activities of aurones or semisynthetic aurones analogs were
reported30,31. The terminology “semisynthetic” refers to compounds bearing the parent
10

aurone pharmacophore found in nature but also possessing unnatural fragments introduced
by chemists in a laboratory setting.

Figure 1.5: Aurone synthase converts chalcones through hydroxylation and oxidative
cyclization to aureusidin through the shikimate pathway. This figure is adapted from Vogt
T., Molecular Plant, 2010, 3(1):2-20.

11

Aurones possess antiparasitic, antimicrobial, anti-viral, anti-inflammatory, and
antineoplastic bioactivities31, and aurone analogs as potential cancer therapeutics are the
focus of this dissertation. Past research in aurones for cancer treatment involves several
unrelated areas of research. A transmembrane drug transporter, P-glycoprotein (Pgp), was
shown to mediate antineoplastic drug resistance by unwanted export of drugs from tumor
cells32, and a number of aurone analogs based on 4-hydroxy-6-methoxyaurones were
reported to bind to the cytosolic domain of P-glycoprotein33. One of these reported
compounds, 5,7-dimethoxyaurone, inhibited Pgp and thereby increased daunorubicin
cytotoxicity on resistant K562 cells.
Cyclin-dependent kinases are well-established targets in cancer therapy34 and a
flavonoid cyclin-dependent kinase inhibitor flavopiridol, was approved by the FDA for the
treatment of acute myeloid leukemia35. Novartis developed an aurone mimic of flavopiridol
and this mimic was as potent as flavopiridol as a cyclin-dependent kinase inhibitor36.
Telomerase, the enzyme responsible for maintaining the length of telomeres, was
activated in many human cancers and was extensively studied as a target for cancer
treatment37. A series of aurone analogs, namely 6,7-dihydroxyaurones, were reported as
telomerase inhibitors30 and the most potent one, 3’,4’-dichloro-6,7-dihydroxyaurone,
showed an IC50 of 300 nM.
Finally, Wyeth reported an interesting set of benzofuran-3-one indole aurone
derivatives as inhibitors of PI3 kinase-α and the mammalian target of rapamycin38. Analog
32 showed strong potency against PI3 kinase-alpha with an IC50 of 40 nM and displayed
an IC50 of 3 μM on PC-3 cell proliferation inhibition assays. Because the related targets
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were determined by looking at the downstream signaling of phosphorylated Akt and
computational docking, the exact mechanism of action was unclear.
In summary, despite these unrelated prior studies, the naturally occuring aurone
scaffold represents a valuable starting point for identifying novel antineoplastic agents and
warrants further effort to address following problems. Firstly , the exact mechanism of
action and direct binding targets of previous aurones are often unclear. Secondly, the
potency of the reported aurone analogs requires improvement to the low nanomolar range.
Developing aurone analogs with clear mechanisms of action requires aurones with a level
of chemical complexity that will result in strong binding affinity to a specific target. This
reduction to the low nanomolar range will also reduce possible off-target side effects.
Thirdly, although tumor cell lines were used in the testing of the reported aurone analogs,
the in vivo antineoplastic potential these agents must be explored.

Dissertation objectives
The long-term goal of this project is to develop specific aurone analogs as potential
antineoplastic drugs. There are three specific aims of this dissertation
Aim 1: To synthesize new aurone derivatives and identify promising, potent
leading compounds suitable for pharmaceutical development.
Aim 2a: To understand the precise molecular mechanisms and identify the direct
biological target(s) of the potent leading compounds using biotinylated aurone derivatives.
Aim 2b: To perform target characterization and validation.
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Aim 3: To perform in vivo evaluation of the antineoplastic effects of potent leading
compounds.
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Chapter 2 Materials and Methods
Chemistry
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO) or Fisher
Scientific (Pittsburgh, PA) unless otherwise noted or were synthesized according to
literature procedures. Solvents were used from commercial vendors without further
purification unless otherwise noted. Nuclear magnetic resonance spectra were determined
on Varian instruments (1H, 400 or 500MHz; 13C, 100 or 126Mz). Low-resolution mass
spectra were obtained using an Agilent 1100 (atmospheric pressure, chemical ionization)
instrument. High resolution mass data were obtained by direct infusion electrospray
ionization mass spectrometry (-MS) using a LTQ-Orbitrap mass spectrometer coupled with
a Heated Electrospray Ionization (HESI-II) Probe (Thermo Fisher Scientific, Waltham,
MA) and an FT analyzer at a resolution of 100,000. The reported m/z mass was a mean of
20 scans. Melting points were determined in open capillarity tubes with a Buchi B-535
apparatus and are uncorrected. Compounds were purified by chromatography on
preparative layer Merck silica gel F254 unless otherwise noted.
General procedure for the synthesis of aurones 3a-3f and 4a-4o
To a suspension of 10 mmol of 6-hydroxybenzofuran-3(2H)-one (2) (Ark Pharm,
Arlington Heights, IL USA) in 20 mL of a 1:1 mixture of DMF and absolute ethanol was
added 2.3 mL of 50% aqueous potassium hydroxide. To this clear solution, obtained after
stirring for ca. 30 min, was added 10 mmol of the appropriate carboxaldehyde. The mixture
was stirred for 6-8 hours at 25 ̊C. The mixture was diluted with 100 mL of hot water,
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acidified with glacial acetic acid pH 5. The resulting precipitate was collected by filtration,
washed with water, dried and re-crystallized from DMF-methanol.
(2Z)-6-Hydroxy-2-(4-pyrrolidin-1-ylbenzylidene)-1-benzofuran-3(2H)-one

Yellow crystals (83% yield); mp >220oC; 1H NMR (400

O

HO

(3a).

MHz, DMSO-d6) δ 1.83-2.07 (m, 4H), 3.26-3.32 (m, 4H),

O

6.61 (d, J = 8.9 Hz, 2H), 6.66-6.72 (m, 2H), 6.77 (d, J = 1.9
N

Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 8.9 Hz, 2H),

11 ppm (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 24.95, 47.24, 98.42, 111.97, 112.58,
112.94, 113.69, 118.62, 125.39, 133.16, 144.73, 148.49, 165.58, 166.87, 180.64 ppm; MS
(ACPI) m/z 308.1 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C19H17NO3
308.1281; Found 308.1279.
(2Z)-6-Hydroxy-2-(4-morpholin-4-ylbenzylidene)-1-benzofuran-3(2H)-one
O

HO

(3b).

Yellow crystals (78% yield); mp >220oC; 1H NMR (400
MHz, DMSO-d6) δ 3.15-3.30 (m, 4H), 3.63-3.80 (m, 4H),

O

6.70 (dd, J = 8.4, 2 Hz, 1H), 6.73 (s, 1H), 6.78 (d, J = 1.9

N
O

Hz, 1H), 7.02 (d, J = 9 Hz, 2H), 7.59 (d, J = 8.4 Hz, 1H),

7.82 (d, J = 9 Hz, 2H), 11.09 ppm (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 47.04, 65.89,
98.52, 111.66, 112.78, 113.35, 114.27, 121.93, 125.64, 132.71, 145.65, 151.64, 165.98,
167.29, 181.02 ppm; MS (ACPI) m/z 324.1 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+
Calcd for C19H17NO4 324.1230; Found 324.1228.
(2Z)-6-Hydroxy-2-[4-(4-methylpiperazin-1-yl)benzylidene]-1-benzofuran-3(2H)-one
hydrochloride (3c). Yellow crystals (77% yield); mp >220oC; 1H NMR (400 MHz,
DMSO-d6) δ 2.83 (s, 3H), 3.04-3.24 (m, 4H), 3.4-3.6 (m, 2H), 3.9-4.2 (m, 2H), 6.72 (dd, J
16

O

HO

= 8.4, 2 Hz, 1H), 6.75 (s, 1H), 6.8 (d, J = 2 Hz, 1H), 7.11
(d, J = 9.2 Hz, 2H), 7.60 (d, J = 8.4 Hz, 1H), 7.86 (d, J

O

= 9.2 Hz, 2H), 10.2 (s, 1H), 11.16 ppm (s, 1H); 13C NMR
N

(100 MHz, DMSO-d6) δ 41.9, 44.3, 51.7, 98.5, 111.2,
N
Me

112.9, 113.2, 115.2, 122.8, 125.7, 132.7, 145.9, 150.1,

166.3, 167.4, 181.1 ppm; MS (ACPI) m/z 337.1 (MH+, 100); HRMS (ESI/HESI) m/z:
[M+H]+ Calcd for C20H20N2O3 337.1547; Found 337.1543.
(2Z)-6-Hydroxy-2-[(4-thiomorpholin-4-ylbenzylidene)]-1-benzofuran-3(2H)-one (3d).
Yellow crystals (84% yield); mp >220oC; 1H NMR (400

O

HO

MHz, DMSO-d6) δ 2.58-2.68 (m, 4H), 3.56-3.86 (m, 4H),

O

6.7 (dd, J = 8.4, 1.9 Hz, 1H), 6.72 (s, 1H), 6.77 (d, J = 1.9
N

Hz, 1H), 7 (d, J = 9 Hz, 2H), 7.59 (d, J = 8.4 Hz, 1H), 7.81
S

(d, J = 9 Hz, 2H), 11.05 ppm (s, 1H); 13C NMR (100 MHz,

DMSO-d6) δ 24.82, 49.69, 98.44, 111.76, 112.72, 113.39, 114.64, 120.9, 125.56, 133.02,
145.47, 150.15, 165.87, 167.16, 180.89 ppm; MS (ACPI) m/z 340.1 (MH+, 100); HRMS
(ESI/HESI) m/z: [M+H]+ Calcd for C19H17NO3S 340.1002; Found 340.0998.
(2Z)-2-[2-Chloro-4-(dimethylamino)benzylidene]-6-hydroxy-1-benzofuran-3(2H)one (3e). Yellow crystals (83% yield); mp >220oC; 1H NMR (400 MHz, DMSO-d6) δ 3.01
O

HO

O

(s, 6H), 6.71 (dd, J = 8.4, 2 Hz, 1H), 6.77 (d, J = 1.9 Hz, 1H),
Cl

6.79-6.84 (m, 2H), 6.95 (s, 1H), 7.6 (d, J = 8.4 Hz, 1H), 8.16
(d, J = 9.7 Hz, 1H), 11.1 ppm (s, 1H); 13C NMR (100 MHz,

N

DMSO-d6) δ 39.59, 98.52, 106.31, 111.27, 111.86, 112.86,

113.14, 115.87, 125.69, 132.51, 136.25, 145.7, 151.44, 166.02, 167.2, 180.77 ppm; MS
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(ACPI) m/z 316.2 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C17H14ClNO3
316.0735; Found 316.0733.
(2Z)-2-[4-(Diethylamino)-2-methoxybenzylidene]-6-hydroxy-1-benzofuran-3(2H)one (3f). Yellow crystals (75% yield); mp >220oC; 1H NMR (400 MHz, DMSO-d6) δ 1.15
O

HO

(t, J = 7 Hz, 7H), 3.44 (q, J = 7 Hz, 4H), 3.88 (s, 3H), 6.22
OMe

O

(d, J = 2.4 Hz, 1H), 6.43 (dd, J = 9, 2.4 Hz, 1H), 6.68 (dd,
J = 8.4, 2 Hz, 1H), 6.75 (d, J = 2 Hz, 1H), 7.05 (s, 1H), 7.56

N

(d, J = 8.4 Hz, 1H), 8.03 (d, J = 9 Hz, 1H), 10.93 ppm (s,

1H); 13C NMR (100 MHz, DMSO-d6) δ 12.55, 43.96, 55.47, 93.64, 98.34, 104.78, 106.17,
107.43, 112.46, 113.8, 125.26, 132.59, 144.45, 150.55, 160.29, 165.33, 166.56, 180.43
ppm; MS (ACPI) m/z 340.2 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for
C20H21NO4 340.1543; Found 340.1540.
(2Z)-6-Hydroxy-2-(isoquinolin-1-ylmethylene)-1-benzofuran-3(2H)-one (4a). Yellow
crystals (78% yield); mp >220oC; 1H NMR (400 MHz,

O

HO

O

DMSO-d6) δ 6.71-6.76 (m, 2H), 7.43 (s, 1H), 7.69 (d, J =
N

8.3 Hz, 1H), 7.7-7.77 (m, 1H), 7.79-7.85 (m, 1H), 7.87 (d,

J = 5.6 Hz, 1H), 8.03 (d, J = 8.1 Hz, 1H), 8.35 (d, J = 8.9 Hz, 1H), 8.69 (d, J = 5.6 Hz, 1H),
11.3 ppm (s, 1H);

13

C NMR (100 MHz, DMSO-d6) δ 98.78, 105.12, 112.39, 113.23,

120.99, 125, 126.42, 127.44, 128.25, 130.59, 135.8, 142.65, 149.81, 151.34, 167.15,
169.05, 182.01 ppm; MS (ACPI) m/z 290.2 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+
Calcd for C18H11NO3 290.0812; Found 290.0810.
(2Z)-6-Hydroxy-2-(quinolin-2-ylmethylene)-1-benzofuran-3(2H)-one (4b). Yellow
crystals (72% yield); mp 249-251oC; 1H NMR (400 MHz, DMSO-d6) δ 6.75 (dd, J = 8.4,
18

2 Hz, 1H), 6.78-6.9 (m, 2H), 7.56-7.73 (m, 2H), 7.75-7.88

O

HO

O

N

(m, 1H), 7.93-8.13 (m, 2H), 8.29 (d, J = 8.7 Hz, 1H), 8.48
(d, J = 8.7 Hz, 1H), 11.39 ppm (s, 1H); 13C NMR (126 MHz,
DMSO-d6) δ 98.84, 110, 112.29, 113.41, 122.62, 126.29,

126.88, 127.47, 127.79, 129.08, 130.11, 136.72, 147.82, 149.55, 151.88, 167.13, 168.36,
181.53 ppm; MS (ACPI) m/z 290.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd
for C18H11NO3 290.0812; Found 290.0806.
(2Z)-6-Hydroxy-2-[(8-methoxyquinolin-2-yl)methylene]-1-benzofuran-3(2H)-one
(4c). Yellow crystals (68% yield); mp 250-252oC; 1H NMR (400 MHz, DMSO-d6) δ 4 (s,
O

HO

O

3H), 6.75 (dd, J = 8.5, 2 Hz, 1H), 6.81 (s, 1H), 6.85 (d,
N

OMe

J = 2 Hz, 1H), 7.09-7.30 (m, 1H), 7.45-7.62 (m, 2H),
7.67 (d, J = 8.5 Hz, 1H), 8.3 (d, J = 8.7 Hz, 1H), 8.42
(d, J = 8.7 Hz, 1H), 11.38 ppm (s, 1H); 13C NMR (100

MHz, DMSO-d6) δ 55.75, 98.59, 109.12, 110.09, 112.2, 113.21, 119.05, 122.67, 125.9,
127.71, 127.77, 136.19, 139.81, 149.11, 150.13, 155.13, 166.87, 168.12, 181.22 ppm; MS
(ACPI) m/z 320.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C19H13NO4
320.0917; Found 320.0919.
(2Z)-2-[(1-Ethyl-5-methoxy-1H-indol-3-yl)methylene]-6-hydroxy-1-benzofuran3(2H)-one (4d). Yellow crystals (77% yield); mp 265-267oC; 1H NMR (400 MHz, DMSOO

HO

d6); δ 1.39 (t, J = 7.2 Hz, 3H), 3.85 (s, 3H), 4.27 (q, J
OMe

O
N
Et

= 7.2 Hz, 2H), 6.72 (dd, J = 8.4, 2 Hz, 1H), 6.83 (d, J
= 2 Hz, 1H), 6.87 (dd, J = 8.9, 2.4 Hz, 1H), 7.23 (s,
1H), 7.42 (d, J = 8.8 Hz, 1H), 7.56-7.64 (m, 2H), 8.18
19

(s, 1H), 10.98 ppm (s, 1H); 13C NMR (126 MHz, DMSO-d6); δ 15.38, 41.3, 55.46, 98.49,
101.1, 105.37, 107.42, 111.41, 112.56, 112.76, 114.38, 125.36, 128.22, 130.74, 133.5,
144.76, 155.02, 165.47, 166.52, 180.12 ppm; MS (ACPI) m/z 336.0 (MH+, 100); HRMS
(ESI/HESI) m/z: [M+H]+ Calcd for C20H17NO4 336.1230; Found 336.1224.
(2Z)-6-Hydroxy-2-(4-pyrrolidin-1-ylbenzylidene)-1-benzofuran-3(2H)-one

Yellow crystals (83% yield); mp >220oC; 1H NMR (400

O

HO

(4e).

MHz, DMSO-d6) δ 1.83-2.07 (m, 4H), 3.26-3.32 (m, 4H),

O

6.61 (d, J = 8.9 Hz, 2H), 6.66-6.72 (m, 2H), 6.77 (d, J = 1.9
N

Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 8.9 Hz, 2H),

11 ppm (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 24.95, 47.24, 98.42, 111.97, 112.58,
112.94, 113.69, 118.62, 125.39, 133.16, 144.73, 148.49, 165.58, 166.87, 180.64 ppm; MS
(ACPI) m/z 308.1 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C19H17NO3
308.1281; Found 308.1279.
(2Z)-6-Hydroxy-2-[(6-methoxyquinolin-2-yl)methylene]-1-benzofuran-3(2H)-one
(4f). Yellow crystals (70% yield); mp 269-271oC; 1H NMR (400 MHz, DMSO-d6) δ 3.91
O

HO

O

(s, 3H), 6.74 (dd, J = 8.4, 2 Hz, 1H), 6.77 (s, 1H), 6.83
(d, J = 2 Hz, 1H), 7.34-7.48 (m, 2H), 7.65 (d, J = 8.4

N

Hz, 1H), 7.94 (d, J = 9 Hz, 1H), 8.24 (d, J = 8.7 Hz,
OMe

1H), 8.35 ppm (d, J = 8.7 Hz, 1H); 13C NMR (100 MHz,

DMSO-d6) δ 55.43, 98.57, 105.61, 110.07, 112.12, 113.27, 122.35, 122.71, 125.84, 128.02,
130.45, 135.1, 143.82, 148.85, 149.1, 158.02, 167.07, 168.12, 181.16 ppm; MS (ACPI)
m/z 320.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C19H13NO4 320.0917;
Found 320.0912.
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(2Z)-6-Hydroxy-2-[(8-methoxyquinolin-2-yl)methylene]-1-benzofuran-3(2H)-one
(4g). Yellow crystals (68% yield); mp 250-252oC; 1H NMR (400 MHz, DMSO-d6) δ 4 (s,
O

HO

3H), 6.75 (dd, J = 8.5, 2 Hz, 1H), 6.81 (s, 1H), 6.85 (d,

O

N

OMe

J = 2 Hz, 1H), 7.09-7.30 (m, 1H), 7.45-7.62 (m, 2H),
7.67 (d, J = 8.5 Hz, 1H), 8.3 (d, J = 8.7 Hz, 1H), 8.42
(d, J = 8.7 Hz, 1H), 11.38 ppm (s, 1H); 13C NMR (100

MHz, DMSO-d6) δ 55.75, 98.59, 109.12, 110.09, 112.2, 113.21, 119.05, 122.67, 125.9,
127.71, 127.77, 136.19, 139.81, 149.11, 150.13, 155.13, 166.87, 168.12, 181.22 ppm; MS
(ACPI) m/z 320.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C19H13NO4
320.0917; Found 320.0919.
(2Z)-6-Hydroxy-2-(quinolin-4-ylmethylene)-1-benzofuran-3(2H)-one (4h).
O

HO

Yellow

crystals (64% yield); mp 278-280oC; 1H NMR (400 MHz,
DMSO-d6) δ 6.76 (dd, J = 8.5, 2 Hz, 1H), 6.81 (d, J = 2

O
N

Hz, 1H), 7.39 (s, 1H), 7.61-7.75 (m, 2H), 7.78-7.91 (m,

1H), 8.09 (dd, J = 8.4, 1.3 Hz, 1H), 8.15 (d, J = 4.6 Hz, 1H), 8.34 (dd, J = 8.5, 1.4 Hz, 1H),
9.03 (d, J = 4.6 Hz, 1H), 11.4 ppm (s, 1H);
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C NMR (100 MHz, DMSO-d6) δ 98.54,

102.42, 112.17, 113.13, 121.61, 123.19, 125.5, 125.84, 126.86, 129.12, 129.49, 135.85,
147.94, 149.72, 150.05, 166.79, 168.06, 180.62 ppm; MS (ACPI) m/z 290.0 (MH+, 100);
HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C18H11NO3 290.0812; Found 290.0812.
(2Z)-6-Hydroxy-2-(1H-indol-3-ylmethylene)-1-benzofuran-3(2H)-one (4i).

Yellow

crystals (55% yield); mp 280-282oC; 1H NMR (400 MHz, DMSO-d6) δ 6.72 (dd, J = 8.5,
O

HO

2 Hz, 1H), 6.85 (d, J = 2 Hz, 1H), 7.11-7.28 (m, 3H), 7.51

O

(d, J = 7.8 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 8.01 (d, J = 7.7
N
H
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Hz, 1H), 8.21 (d, J = 2.8 Hz, 1H), 10.99 (s, 1H), 11.99 ppm (s, 1H); 13C NMR (126 MHz,
DMSO-d6) δ 98.75, 105.36, 108.49, 112.4, 112.76, 114.45, 118.98, 120.86, 122.74, 125.52,
126.9, 131.31, 136.43, 145.43, 165.79, 166.9, 180.52 ppm; MS (ACPI) m/z 278.2 (MH+,
100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C17H11NO3 278.0812; Found 278.0813.
(2Z)-6-Hydroxy-2-[(1-methyl-1H-indol-3-yl)methylene]-1-benzofuran-3(2H)-one
(4j). Yellow crystals (78% yield); mp 272-274oC; 1H NMR (400 MHz, DMSO-d6) δ 3.9
O

HO

(s, 3H), 6.72 (d, J = 8.4 Hz, 1H), 6.83 (s, 1H), 7.13-7.32 (m,
3H), 7.51 (d, J = 8 Hz, 1H), 7.6 (d, J = 8.1 Hz, 1H), 7.99 (d,

O
N
Me

J = 7.8 Hz, 1H), 8.19 (s, 1H), 11.02 ppm (s, 1H); 13C NMR
(126 MHz, DMSO-d6) δ 33.13, 98.48, 104.67, 107.3,

110.54, 112.6, 114.26, 118.96, 120.96, 122.64, 125.41, 127.2, 134.74, 136.76, 145.12,
165.57, 166.65, 180.17 ppm; MS (ACPI) m/z 292.0 (MH+, 100); HRMS (ESI/HESI) m/z:
[M+H]+ Calcd for C18H13NO3 292.0968; Found 292.0962.
(2Z)-6-Hydroxy-2-[(5-methoxy-1-methyl-1H-indol-3-yl)methylene]-1-benzofuran3(2H)-one (4k). Yellow crystals (82% yield); mp 301-303oC; 1H NMR (400 MHz,
O

HO

DMSO-d6) δ 3.84 (s, 3H), 3.86 (s, 3H), 6.71 (dd, J =
OMe

O
N
Me

8.5, 2 Hz, 1H), 6.82 (d, J = 2 Hz, 1H), 6.88 (dd, J =
8.7, 2.4 Hz, 1H), 7.21 (s, 1H), 7.39 (d, J = 8.8 Hz, 1H),
7.53-7.64 (m, 2H), 8.12 (s, 1H), 11.03 ppm (s, 1H); 13C

NMR (126 MHz, DMSO-d6) δ 33.28, 55.45, 98.41, 100.92, 105.32, 107.19, 111.38,
112.54, 112.73, 114.33, 125.32, 127.99, 131.82, 134.99, 144.74, 155.05, 165.48, 166.48,
180.07 ppm; MS (ACPI) m/z 322.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd
for C19H15NO4 322.1074; Found 322.1067.
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(2Z)-2-[(1-Ethyl-5-methoxy-1H-indol-3-yl)methylene]-6-hydroxy-1-benzofuran3(2H)-one (4l). Yellow crystals (77% yield); mp 265-267oC; 1H NMR (400 MHz, DMSOO

d6); δ 1.39 (t, J = 7.2 Hz, 3H), 3.85 (s, 3H), 4.27 (q, J = 7.2
Hz, 2H), 6.72 (dd, J = 8.4, 2 Hz, 1H), 6.83 (d, J = 2 Hz, 1H),

O

HO

6.87 (dd, J = 8.9, 2.4 Hz, 1H), 7.23 (s, 1H), 7.42 (d, J = 8.8

N
Et

Hz, 1H), 7.56-7.64 (m, 2H), 8.18 (s, 1H), 10.98 ppm (s, 1H);

13

C NMR (126 MHz, DMSO-d6); δ 15.38, 41.3, 55.46, 98.49, 101.1, 105.37, 107.42,

111.41, 112.56, 112.76, 114.38, 125.36, 128.22, 130.74, 133.5, 144.76, 155.02, 165.47,
166.52, 180.12 ppm; MS (ACPI) m/z 336.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+
Calcd for C20H17NO4 336.1230; Found 336.1224.
(Z)-2-((2-((1-Ethyl-5-methoxy-1H-indol-3-yl)methylene)-3-oxo-2,3dihydrobenzofuran-6-yl)oxy)acetonitrile (5a). To a solution of 670 mg (2 mmol) of (2Z)O

NC

O

2-[(1-ethyl-5-methoxy-1H-indol-3OMe

O
N
Et

yl)methylene]-6-hydroxy-1-benzofuran-3(2H)one (4d) in 10 mL of DMF was added 830 mg (6
mmol, 3 eq) of anhydrous potassium carbonate.

The mixture was heated to 60oC and 0.152 mL (2.4 mmol, 1.2 eq) of chloroacetonitrile was
added. The mixture was stirred at 60oC for an additional 8 hours, cooled, and poured into
100 mL of 0.1N aqueous sulfuric acid. The precipitate was collected by filtration, washed
with water, dried and re-crystallized from DMF-methanol to afford 487 mg (65%) of 5a as
yellow crystals: mp 230-232oC; 1H NMR (400 MHz, DMSO-d6) δ 1.44 (d, J = 7.2 Hz, 3H),
3.86 (s, 3H), 4.33 (q, J = 7.2 Hz, 2H), 5.39 (s, 2H), 6.9 (dd, J = 8.9, 2.4 Hz, 1H), 6.97 (dd,
J = 8.6, 2.2 Hz, 1H), 7.29 (d, J = 2.2 Hz, 1H), 7.37 (s, 1H), 7.51 (d, J = 8.9 Hz, 1H), 7.63
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(d, J = 2.4 Hz, 1H), 7.77 (d, J = 8.6 Hz, 1H), 8.23 ppm (s, 1H);

13

C NMR (100 MHz,

DMSO-d6) δ 14.67, 40.97, 53.89, 55.34, 98.17, 101.45, 106.18, 107.17, 110.99, 111.68,
112.46, 115.45, 116.87, 124.84, 127.89, 130.8, 133.46, 144.2, 154.96, 162.6, 165.49,
179.58 ppm; MS (ACPI) m/z 375.2 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd
for C22H19N2O4 375.1339; Found 375.1337.
(Z)-2-((2-((1-Ethyl-5-hydroxy-1H-indol-3-yl)methylene)-3-oxo-2,3dihydrobenzofuran-6-yl)oxy)acetonitrile (5b). To 36 mg (0.11 mmol, 1 eq) of 5-(tertO

NC

O

butyldimethylsilyloxy)-1-ethyl-1H-indole-3OH

O
N
Et

carboxaldehyde

in

2

mL

of

anhydrous

dichloromethane was added 30 mg (0.16 mmol, 1.4
eq)

of

2-((3-oxo-2,3-dihydrobenzofuran-6-

yl)oxy)acetonitrile and 366 mg (3.6 mmol, 32 eq) of alumina (Sigma-Aldrich, St. Louis,
MO.). The mixture was stirred at 25oC for 6 hours, filtered and concentrated. The residue
was treated with 824 µL of a 1M (2.5 eq) solution of tetra(n-butyl)ammonium fluoride in
tetrahydrofuran for 1 hour at 25oC. The product was recrystallized from ca. 1:1 methanoldichloromethane to afford 24 mg (60%) of 4b as yellow crystals: mp 208-210oC; 1H NMR
(400 MHz, DMSO-d6) δ 1.43 (t, J = 7.2 Hz, 4H), 4.29 (q, J = 7.2 Hz, 2H), 5.38 (s, 2H), 6.8
(dd, J = 8.8, 2.2 Hz, 1H), 6.96 (dd, J = 8.6, 2.1 Hz, 1H), 7.11 (s, 1H), 7.3 (dd, J = 6.4, 2.1
Hz, 2H), 7.76 (d, J = 8.5 Hz, 1H), 8.17 (s, 1H), 9.16 ppm (s, 1H); 13C NMR (100 MHz,
DMSO-d6) δ 15.35, 41.35, 54.05, 98.26, 103.37, 106.73, 106.76, 111.45, 112.11, 112.83,
116.19, 117.02, 125.35, 128.45, 134.08, 144.17, 152.8, 162.79, 165.73, 179.84 ppm;
HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C21H16N2O4 361.1183; Found 361.1180.
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(Z)-2-(3-((6-(Cyanomethoxy)-3-oxobenzofuran-2(3H)-ylidene)methyl)-5-methoxy1H-indol-1-yl)acetic acid (5c). To a solution of 45 mg (0.24 mmol, 1.2 eq) of 2-(3-oxoO

N

C

O

2,3-dihydrobenzofuran-6-yl)oxy)acetonitrile in
OCH3

O
N
HO2C

3 mL of anhydrous dichloromethane was added
58 mg (0.2 mmol, 1 eq) of tert-butyl 2-(3-formyl5-methoxy-1H-indol-1-yl)acetate and 646 mg

(6.4 mmol, 32 eq) of alumina. The mixture was stirred at 25oC for 6 hours, filtered,
concentrated and recrystallized from ca. 1:4 methanol-dichloromethane, to afford pure tertbutyl (Z)-2-(3-((6-(cyanomethoxy)-3-oxobenzofuran-2(3H)-ylidene)methyl)-5-methoxy1H-indol-1-yl)acetate. This product was refluxed in 2 mL of formic acid at 60oC for 2
hours. The solution was concentrated to afford, 48 mg (60%) of 5c as yellow crystals:
mp >220oC; 1H NMR (400 MHz, DMSO-d6) δ 3.85 (s, 3H), 5.18 (s, 2H), 5.38 (s, 2H), 6.88
(dd, J = 8.9, 2.4 Hz, 1H), 6.97 (dd, J = 8.5, 2.2 Hz, 1H), 7.23 (d, J = 2.1 Hz, 1H), 7.37 (s,
1H), 7.43 (d, J = 8.9 Hz, 1H), 7.63 (d, J = 2.4 Hz, 1H), 7.78 (d, J = 8.5 Hz, 1H), 8.22 (s,
1H), 13.18 ppm (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 54.04, 55.56, 98.11, 100.99,
106.62, 107.83, 111.63, 112.24, 113.01, 116.17, 116.94, 125.52, 128.02, 131.69, 135.55,
144.83, 155.23, 162.94, 165.92, 169.99, 180.10 ppm; MS (ACPI) m/z 391.2 (MH+, 100);
HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C22H17N2O6 405.1081; Found 405.1075.
General procedure for the synthesis of aurones 5d-5q
To a solution of 2 mmol of aurones 4 in 10 mL of N,N-dimethylformamide was
added 830 mg (6 mmol) of anhydrous potassium carbonate. The mixture was heated to
60oC and 2.4 mmol of the appropriate benzyl chloride was added. The mixture was stirred
at 60oC for 8 hours, cooled, and poured into 100 mL of aqueous 0.1N sulfuric acid. The
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precipitate was collected by filtration, washed with water, dried and re-crystallized from
ca. 1:1 N,N-dimethylformamide-methanol.
(2Z)-6-[(2-Fluorobenzyl)oxy]-2-[(1-methyl-1H-indol-3-yl)methylene]-1-benzofuran3(2H)-one (5d). Yellow crystals (76% yield); mp 241-243oC; 1H NMR (400 MHz,
O

O

DMSO-d6) δ 3.93 (s, 3H), 5.34 (s, 2H), 6.93 (dd, J
= 8.4, 2.2 Hz, 1H), 7.14-7.35 (m, 6H), 7.39-7.72 (m,

O
N
Me

F

4H), 8.02 (d, J = 7.8 Hz, 1H), 8.15 ppm (s, 1H); 13C
NMR (126 MHz, CDCl3) δ 33.47, 64.31 (d, J = 4.6

Hz), 97.42, 105.95, 108.57, 109.8, 112.12, 115.52 (d, J = 21.1 Hz), 116.62, 119.17, 121.28,
123.01, 124.44 (d, J = 3.4 Hz), 125.55, 127.87, 129.61, 129.64, 130.18 (d, J = 8.4 Hz),
134.01, 136.96, 146.01, 160.43 (d, J = 247.5 Hz), 165.36, 167, 181.75 ppm; MS (ACPI)
m/z 400.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C25H18FNO3 400.1343;
Found 400.1334.
(2Z)-6-[(2-Chlorobenzyl)oxy]-2-[(1-methyl-1H-indol-3-yl)methylene]-1-benzofuran3(2H)-one (5e).

Yellow crystals (69% yield); mp 206-208oC; 1H NMR (400 MHz,
O

O
Cl

DMSO-d6) δ 3.93 (s, 3H), 5.35 (s, 2H), 6.93 (dd, J
= 8.5, 2.2 Hz, 1H), 7.17-7.36 (m, 4H), 7.38-7.49 (m,

O
N
Me

2H), 7.5-7.59 (m, 2H), 7.6-7.73 (m, 2H), 8.04 (d, J
= 7.7 Hz, 1H), 8.21 ppm (s, 1H);

13

C NMR (126

MHz, CDCl3) δ 33.53, 67.78, 97.54, 106.03, 108.61, 109.92, 112.24, 116.72, 119.18,
121.36, 123.08, 125.56, 127.24, 127.96, 128.82, 129.51, 129.64, 132.74, 133.67, 134.17,
137.01, 146.08, 165.37, 167.04, 181.78 ppm; MS (ACPI) m/z 416.0 (MH+, 100); HRMS
(ESI/HESI) m/z: [M+H]+ Calcd for C25H18ClNO3 416.1048; Found 416.1044.
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(2Z)-6-[(2,6-Difluorobenzyl)oxy]-2-[(1-methyl-1H-indol-3-yl)methylene]-1benzofuran-3(2H)-one (5f). Yellow crystals (73% yield); mp >220oC; 1H NMR (400
O

MHz, DMSO-d6) δ 3.94 (s, 3H), 5.31 (s, 2H), 6.9

F
O

(dd, J = 8.5, 2.1 Hz, 1H), 7.19-7.40 (m, 6H), 7.54-

O
N
Me

F

7.61 (m, 2H), 7.69 (d, J = 8.5 Hz, 1H), 8.08 (d, J =
7.8 Hz, 1H), 8.21 ppm (s, 1H); 13C NMR (100 MHz,

DMSO-d6) δ 33.67, 58.99, 98.11, 106.19, 107.8, 111.09, 111.95 (t, J = 18.7 Hz), 112.36
(d, J = 24.2 Hz), 112.88, 116.21, 119.65, 121.54, 123.22, 125.56, 127.5, 132.56 (t, J = 10.2
Hz), 135.55, 137.28, 145.29, 161.63 (dd, J = 256.8, 7.1 Hz), 165.48, 166.82, 180.58 ppm;
MS (ACPI) m/z 418.2 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for
C25H17F2NO3 418.1249; Found 418.1246.
(2Z)-6-[(2,6-Dichlorobenzyl)oxy]-2-[(1-methyl-1H-indol-3-yl)methylene]-1benzofuran-3(2H)-one (5g). Yellow crystals (65% yield); mp 247-249oC; 1H NMR (400
O

MHz, CDCl3) δ 3.9 (s, 3H), 5.4 (s, 2H), 6.84 (dd, J

Cl
O
Cl

= 8.5, 2.1 Hz, 1H), 6.95 (d, J = 2.1 Hz, 1H), 7.18-

O
N
Me

7.48 (m, 7H), 7.75 (d, J = 8.5 Hz, 1H), 7.92 (d, J =
7.7 Hz, 1H), 7.97 ppm (s, 1H); 13C NMR (100 MHz,

CDCl3) δ 33.63, 65.82, 97.65, 106.12, 108.75, 109.96, 112.23, 116.81, 119.33, 121.43,
123.16, 125.67, 128.01, 128.72, 131, 131.28, 134.2, 137.1, 137.18, 146.18, 165.83, 167.1,
181.94 ppm; MS (ACPI) m/z 450.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd
for C25H17Cl2NO3 450.0658; Found 450.0650.
(2Z)-6-[(2-Chloro-6-fluorobenzyl)oxy]-2-[(1-methyl-1H-indol-3-yl)methylene]-1benzofuran-3(2H)-one (5h). Yellow crystals (76% yield); mp 225-227oC; 1H NMR
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(400 MHz, CDCl3) δ 3.87 (s, 3H), 5.28 (d, J = 1.8

O
Cl

Hz, 2H), 6.8 (dd, J = 8.5, 2.1 Hz, 1H), 6.91 (d, J =
O

O

N
Me

F

2.1 Hz, 1H), 7.03-7.13 (m, 1H), 7.24-7.41 (m, 6H),
7.72 (d, J = 8.5 Hz, 1H), 7.90 (d, J = 7.6 Hz, 1H),

7.94ppm (s, 1H); 13C NMR (126 MHz, CDCl3) δ 33.59, 61.83 (d, J = 4.1 Hz), 97.63,
106.05, 108.73, 109.94, 112.17, 114.57 (d, J = 22.5 Hz), 116.79, 119.3, 121.41, 121.61
(d, J = 17.4 Hz), 123.14, 125.62, 125.82 (d, J = 3.3 Hz), 128, 131.31 (d, J = 9.7 Hz),
134.18, 136.74 (d, J = 4.6 Hz), 137.09, 146.16, 162.12 (d, J = 251.8 Hz), 165.64, 167.07,
181.89 ppm; MS (ACPI) m/z 434.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd
for C25H17ClFNO3 434.0954; Found 434.0949.
(2Z)-6-[(2,6-Dichlorobenzyl)oxy]-7-methyl-2-[(1-methyl-1H-indol-3-yl)methylene]-1benzofuran-3(2H)-one (5i). Yellow crystals (87% yield); mp 232-234oC; 1H NMR (400
O

MHz, DMSO-d6) δ: 2.25 (s, 3H), 3.93 (s, 3H), 5.40

Cl

Cl

(s, 2H), 7.15-7.33 (m, 4H), 7.46-7.62 (m, 4H),

O

O
Me

N
Me

7.66 (d, J = 8.5 Hz, 1H), 8.05 (d, J = 7.9 Hz, 1H),
8.12 ppm (s, 1H); 13C NMR (126 MHz, CDCl3) δ

8.16, 33.57, 66.25, 105.45, 107.75, 108.88, 109.85, 110.91, 116.61, 119.22, 121.23,
122.6, 123.01, 127.89, 128.62, 130.73, 131.71, 134, 136.96, 137.05, 146.24, 163.15,
164.54, 182.64 ppm; MS (ACPI) m/z 464.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+
Calcd for C26H19Cl2NO3 464.0815; Found 464.0811.
(2Z)-6-[(2-Chloro-4-fluorobenzyl)oxy]-2-[(5-methoxy-1-methyl-1H-indol-3yl)methylene]-1-benzofuran-3(2H)-one (5j). Yellow crystals (85% yield); mp 184186oC; 1H NMR (400 MHz, DMSO-d6) δ 3.85 (s, 3H), 3.89 (s, 3H), 5.3 (s, 2H), 6.85-
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6.97 (m, 2H), 7.20 (d, J = 2.1 Hz, 1H),

O
O

O
F

OMe

1H), 7.56 (dd, J = 8.9, 2.6 Hz, 1H), 7.61

N
Me

Cl

7.26-7.37 (m, 2H), 7.45 (d, J = 8.9 Hz,

(d, J = 2.4 Hz, 1H), 7.65-7.75 (m, 2H),

8.16 ppm (s, 1H); 13C NMR (126 MHz, CDCl3) δ 33.66, 55.84, 67.19, 97.45, 100.58,
106.26, 108.23, 110.78, 111.98, 113.39, 114.44 (d, J = 21.1 Hz), 116.8, 117.08 (d, J =
24.9 Hz), 125.4, 128.63, 129.66 (d, J = 3.6 Hz), 130.14 (d, J = 9 Hz), 132.03, 133.55 (d, J
= 10.5 Hz), 134.43, 145.67, 155.62, 162.34 (d, J = 250.5 Hz), 165.03, 166.78, 181.59
ppm; MS (ACPI) m/z 464.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for
C26H19ClFNO4 464.1059; Found 464.1049.
(2Z)-6-[(2-Chloro-6-fluorobenzyl)oxy]-2-[(5-methoxy-1-methyl-1H-indol-3yl)methylene]-1-benzofuran-3(2H)-one (5k). Yellow crystals (71% yield); mp 200202oC; 1H NMR (400 MHz, DMSO-d6) δ

O
F
O
Cl

OMe

O
N
Me

3.85 (s, 3H), 3.9 (s, 3H), 5.33 (d, J = 1.8 Hz,
2H), 6.86-6.95 (m, 2H), 7.26-7.4 (m, 3H),
7.42-7.49 (m, 2H), 7.51-7.6 (m, 1H), 7.62 (d,

J = 2.4 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 8.15 ppm (s, 1H); 13C NMR (126 MHz, CDCl3)
δ 33.56, 55.78, 61.65 (d, J = 4.2 Hz), 97.38, 100.51, 106.13, 108.18, 110.73, 111.96,
113.29, 114.43 (d, J = 22.6 Hz), 116.63, 121.47 (d, J = 17.2 Hz), 125.31, 125.67 (d, J =
3.4 Hz), 128.54, 131.18 (d, J = 9.9 Hz), 131.95, 134.42, 136.56 (d, J = 4.8 Hz), 145.63,
155.52, 161.96 (d, J = 251.9 Hz), 165.39, 166.75, 181.59 ppm; MS (ACPI) m/z 464.2
(MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C26H19ClFNO4 464.1059; Found
464.1050.
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(2Z)-6-[(2,6-Dichlorobenzyl)oxy]-2-[(5-methoxy-1-methyl-1H-indol-3-yl)methylene]1-benzofuran-3(2H)-one (5l). Yellow crystals (69% yield); mp 233-235oC; 1H NMR
(400 MHz, CDCl3) δ 3.8 (s, 3H), 3.89 (s, 3H), 5.34 (s, 2H), 6.8 (dd, J = 8.5, 2.1 Hz, 1H),
6.89 (d, J = 2.1 Hz, 1H), 6.93 (dd, J = 8.8, 2.4 Hz, 1H), 7.15-7.41 (m, 6H), 7.71 (d, J =
8.5 Hz, 1H), 7.87 ppm (s, 1H); 13C NMR (126 MHz, CDCl3) δ 33.69, 55.9, 65.74, 97.58,
100.66, 106.22, 108.31, 110.8, 112.07, 113.45, 116.79, 125.49, 128.63, 130.91, 131.23,
132.07, 134.43, 137.09, 145.77, 155.63, 165.68, 166.89, 181.71 ppm; MS (ACPI) m/z
480.0 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C26H19Cl2NO4 480.0764;
Found 480.0754.
(2Z)-6-[(2,6-Dichlorobenzyl)oxy]-2-[(5-methoxy-1-methyl-1H-indol-3-yl)methylene]7-methyl-1-benzofuran-3(2H)-one (5m). Yellow crystals (74% yield); mp 241-243oC;
1

O
Cl

Cl

OMe

O

O
Me

N
Me

H NMR (400 MHz, DMSO-d6) δ 2.25 (s,

3H), 3.84 (s, 3H), 3.9 (s, 3H), 5.41 (s, 2H),
6.9 (dd, J = 8.8, 2.4 Hz, 1H), 7.2 (d, J = 8.5
Hz, 1H), 7.29 (s, 1H), 7.41-7.55 (m, 2H),

7.57-7.63 (m, 3H), 7.66 (d, J = 8.5 Hz, 1H), 8.08 ppm (s, 1H); 13C NMR (126 MHz,
CDCl3) δ 8.21, 33.83, 55.97, 66.32, 100.72, 105.78, 107.83, 108.59, 110.8, 110.96,
113.51, 116.75, 122.66, 128.66, 128.7, 130.76, 131.77, 132.1, 134.27, 137.11, 146.02,
155.62, 163.16, 164.55, 182.67 ppm; MS (ACPI) m/z 494.2 (MH+, 100); HRMS
(ESI/HESI) m/z: [M+H]+ Calcd for C27H21Cl2NO4 494.0920; Found 494.0911.
(2Z)-2-[(1-Ethyl-5-methoxy-1H-indol-3-yl)methylene]-6-[(2-fluorobenzyl)oxy]-1benzofuran-3(2H)-one (5n). Yellow crystals (63% yield); mp 139-141oC; 1H NMR
(400 MHz, DMSO-d6) δ 1.42 (t, J = 7.2 Hz, 3H), 3.85 (s, 3H), 4.29 (q, J = 7.2 Hz, 2H),
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5.31 (s, 2H), 6.83-6.94 (m, 2H), 7.18-7.33

O

O

OMe

O

2H), 7.67 (d, J = 8.5 Hz, 1H), 8.19 ppm (s,

N
Et

F

(m, 4H), 7.4-7.53 (m, 2H), 7.56-7.64 (m,

1H); 13C NMR (126 MHz, CDCl3) δ 15.39,

41.93, 55.79, 64.27 (d, J = 4.6 Hz), 97.36, 100.63, 106.29, 108.29, 110.81, 112.06,
113.32, 115.48 (d, J = 21.1 Hz), 116.63, 123.03 (d, J = 14.2 Hz), 124.43 (d, J = 3.6 Hz),
125.4, 128.78, 129.61 (d, J = 3.6 Hz), 130.15 (d, J = 8.2 Hz), 130.97, 132.69, 145.6,
155.48, 160.41 (d, J = 247.2 Hz), 165.25, 166.82, 181.64 ppm; MS (ACPI) m/z 444.2
(MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C27H22FNO4 444.1606; Found
444.1600.
(2Z)-6-[(2,6-Dichlorobenzyl)oxy]-2-[(1-ethyl-5-methoxy-1H-indol-3-yl)methylene]-1benzofuran-3(2H)-one (5o). Yellow crystals (73% yield); mp 211-213oC; 1H NMR (400
O

MHz, CDCl3) δ 1.54 (t, J = 7.2 Hz, 3H), 3.9

Cl
O
Cl

OMe

O
N
Et

(s, 3H), 4.2 (q, J = 7.2 Hz, 2H), 5.36 (s, 2H),
6.82 (dd, J = 8.6, 2.1 Hz, 1H), 6.89-6.97 (m,
2H), 7.2-7.42 (m, 6H), 7.73 (d, J = 8.5 Hz,

1H), 7.97 ppm (s, 1H); 13C NMR (126 MHz, CDCl3) δ 15.46, 42.02, 55.91, 65.75, 97.62,
100.76, 106.33, 108.42, 110.91, 112.09, 113.41, 116.82, 125.51, 128.63, 128.9, 130.91,
131.09, 131.22, 132.76, 137.09, 145.75, 155.59, 165.68, 166.89, 181.74 ppm; MS (ACPI)
m/z 494.2 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C27H21Cl2NO4
494.0920; Found 494.0917.
(2Z)-6-[(2-Chloro-6-fluorobenzyl)oxy]-2-[(1-ethyl-1H-indol-3-yl)methylene]-1benzofuran-3(2H)-one (5p). Yellow crystals (74% yield); mp 198-200oC; 1H NMR
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(400 MHz, DMSO-d6) δ 1.46 (t, J = 7.2 Hz, 3H),

O
F

4.36 (q, J = 7.2 Hz, 2H), 5.35 (d, J = 1.8 Hz, 2H),
O

O
N
Et

Cl

6.91 (dd, J = 8.5, 2.1 Hz, 1H), 7.21-7.33 (m, 3H),
7.33-7.41 (m, 2H), 7.47 (d, J = 8.1 Hz, 1H), 7.52-

7.59 (m, 1H), 7.61 (d, J = 8.1 Hz, 1H), 7.7 (d, J = 8.5 Hz, 1H), 8.08 (d, J = 7.8 Hz, 1H),
8.28 ppm (s, 1H); 13C NMR (126 MHz, CDCl3) δ 15.31, 41.73, 61.68, 97.46, 105.98,
108.61, 109.95, 112.02, 114.42 (d, J = 22.7 Hz), 116.6, 119.18, 121.22, 121.44 (d, J =
17.2 Hz), 122.88, 125.36, 125.66, 128.06, 131.18 (d, J = 9.8 Hz), 132.51, 135.96, 136.55
(d, J = 4.8 Hz), 145.95, 161.95 (d, J = 252.5 Hz), 165.46, 166.87, 181.69 ppm; MS
(ACPI) m/z 448.2 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+ Calcd for C26H19ClFNO3
448.1110; Found 448.1108.
(2Z)-6-[(2,6-Dichlorobenzyl)oxy]-2-[(1-ethyl-1H-indol-3-yl)methylene]-1benzofuran-3(2H)-one (5q). Yellow crystals (68% yield); mp 213-215oC; 1H NMR
O

(400 MHz, DMSO-d6) δ 1.46 (t, J = 7.2 Hz, 3H),

Cl
O
Cl

3.35 (s, 3H), 4.37 (q, J = 7.2 Hz, 2H), 5.43 (s,

O
N
Et

2H), 6.92 (dd, J = 8.5, 2.2 Hz, 1H), 7.18-7.34 (m,

3H), 7.40 (d, J = 2.2 Hz, 1H), 7.52 (dd, J = 8.9, 7.2 Hz, 1H), 7.59-7.65 (m, 3H), 7.71 (d, J
= 8.5 Hz, 1H), 8.05-8.13 (m, 1H), 8.29 ppm (s, 1H); 13C NMR (126 MHz, CDCl3) δ
15.43, 41.85, 65.77, 97.6, 106.13, 108.76, 110.03, 112.17, 116.75, 119.35, 121.33,
122.99, 125.55, 128.17, 128.66, 130.93, 131.22, 132.58, 136.08, 137.11, 146.07, 165.75,
167, 181.83 ppm; MS (ACPI) m/z 464.2 (MH+, 100); HRMS (ESI/HESI) m/z: [M+H]+
Calcd for C26H19Cl2NO3 464.0815; Found 464.0806.
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(2Z)-6-[(2,6-Dichlorobenzyl)oxy]-2-(pyridin-4-ylmethylene)-1-benzofuran-3(2H)-one
(5r). To a solution of 1.5 g (10 mmol) of 6-hydroxybenzofuran-3(2H)-one (2) in 30 mL of
O

DMF was added 4.14 g (30 mmol, 3 eq) of anhydrous

Cl
O
Cl

potassium carbonate followed by 2.35 g (12 mmol, 1.2

O
N

eq) of 2,6-dichlorobenzyl chloride (Thermofisher

Acros Organics, Geel, Belgium). The mixture was stirred at 25oC for 8 hours and diluted
with 200 mL of water. The precipitate was collected, washed with water, dried and purified
by column chromatography using 1:100 dichloromethane-methanol to afford 1.79 g (58%)
of 6-((2,6-dichlorobenzyl)oxy)benzofuran-3(2H)-one as pale yellow crystals: mp 153-155
o

C. 1H NMR (400 MHz, CDCl3) δ 4.64 (s, 2H), 5.34 (s, 2H), 6.67-6.77 (m, 2H), 7.29 (d,

J = 7.2 Hz, 1H), 7.33-7.42 (m, 2H), 7.58 (d, J = 9 Hz, 1H); 13C NMR (100 MHz, CDCl3)
δ 65.57, 75.56, 97.32, 111.98, 114.76, 125.15, 128.56, 130.9, 130.96, 136.97, 167.18,
176.32, 197.49 ppm; MS (ACPI) m/z 309.2 (MH+, 100). To 50 mL of a freshly prepared
0.2 M (5 eq) solution of sodium methoxide was added a solution of 618 mg (2 mmol) of 6((2,6-dichlorobenzyl)oxy)benzofuran-3(2H)-one and 214 mg (2 mmol, 1 eq) of 4pyridinecarboxaldehyde in 5 mL of methanol. The mixture was stirred at 25oC for 12 hours.
The solution was concentrated and poured into 100 mL of water at 0oC. The mixture was
acidified with 1N aqueous hydrochloric acid solution to ca. pH 6. The precipitate was
collected by filtration and recrystallized from 2:1 DMF-methanol to afford 445 mg (56%)
of 5r: mp 219-222oC; 1H NMR (400 MHz, CDCl3) δ 5.41 (s, 2H), 6.7 (s, 1H), 6.88 (dd, J
= 8.6, 2.2 Hz, 1H), 6.96 (d, J = 2.2 Hz, 1H), 7.28-7.36 (m, 1H), 7.36-7.45 (m, 2H), 7.687.78 (m, 3H), 8.7 ppm (d, J = 5.2 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 66.04, 98, 108.3,
113.23, 114.8, 124.74, 126.45, 128.78, 130.92, 131.17, 137.19, 139.95, 150.3, 150.36,
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167.19, 168.85, 182.73 ppm; MS (ACPI) m/z 398.0 (MH+, 100); HRMS (ESI/HESI) m/z:
[M+H]+ Calcd for C21H13Cl2NO3 398.0345; Found 398.0349.
Procedure for the synthesis of biotinylated aurone analog 6d

Tert-butyl 2-((3-oxo-2,3-dihydrobenzofuran-6-yl)oxy)acetate
O
O

O
O

O

(6a).

To a flask

containing 0.5 mL of DMF, and 30 mg (0.2 mmol) of 6hydroxybenzofuran-3(2H)-one (Ark pharm, IL, USA) was
added 37 μL (0.24 mmol, 1.2 eq) of tert-Butyl bromoacetate

(Sigma, MO, USA), and 55 mg (0.4 mmol, 2 eq) of potassium carbonate. The mixture was
stirred at 25oC for 16 hours, extracted with DCM (dichloromethane), washed, dried and
chromatographed on SiO2 using 1:10-1:2 ethyl acetate: hexane to afford 31 mg (58%) of
6a as yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 1.43 (s, 9H), 4.77(s, 2H), 4.82(s, 2H),
6.69-6.77 (m, 2H), 7.53-7.55 ppm (d, 2H); 13C NMR (126 MHz, DMSO-d6) δ 27.72, 65.31,
75.55, 81.82, 97.57, 111.54, 114.55, 124.72, 165.96, 167.09, 175.47, 197.26 ppm.
(Z)-tert-butyl2-((2-((1-ethyl-5-methoxy-1H-indol-3-yl)methylene)-3-oxo-2,3O
O

O
O

dihydrobenzofuran-6-yl)oxy)acetate (6b). To

O

O

a flask containing 26 mg (0.1 mmol) of tert-butyl
2-((3-oxo-2,3-dihydrobenzofuran-6-

N

yl)oxy)acetate (6a) in 1 mL of DCM was added
20.3 mg (0.1 mmol, 1 eq) of commercially available 1-ethyl-5-methoxy-1H-indole-3carbaldehyde and 320 mg (3.2 mmol, 32 eq) of aluminum oxide. The mixture was stirred
at 25oC for 16 hours, filtered, concentrated, crystallized in methanol to afford 27 mg (60%)
of 6b as yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 1.41-1.45 (m, 12H), 3.48 (s, 3H),
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4.28-4.34 (q, 2H), 4.88 (s, 2H), 6.83-6.90 (m, 2H), 7.07 (d, 1H), 7.30 (s, 1H), 7.49-7.51
(d, 1H), 7.62-7.69 (m, 2H), 8.19 ppm (s, 1H);

13

C NMR (126 MHz, DMSO-d6) δ 15.79,

28.15, 41.78, 55.92, 65.89, 82.27, 98.27, 101.55, 106.78, 107.82, 111.99, 112.52, 113.30,
116.73, 125.45, 128.63, 131.18, 134.11, 144.97, 155.52, 165.02, 166.48, 167.59, 180.45
ppm.
(Z)-2-((2-((1-ethyl-5-methoxy-1H-indol-3-yl)methylene)-3-oxo-2,3dihydrobenzofuran-6-yl)oxy)acetic acid (6c). (Z)-tert-butyl2-((2-((1-ethyl-5-methoxyO
O

O

1H-indol-3-yl)methylene)-3-oxo-2,3-

O

OH

O

dihydrobenzofuran-6-yl)oxy)acetate (6b) was
refluxed in 2 mL of formic acid at 60 oC for 2

N

hours. The solution was concentrated by
evaporation and further dried in a desiccator to afford 6c (100%) as yellow solid. 1H NMR
(400 MHz, DMSO-d6) δ 1.41-1.45 (t, 3H), 3.84 (s, 3H), 4.29-4.35 (q, 2H), 4.90 (s, 2H),
6.84-6.90 (m, 2H), 7.06 (s, 1H), 7.30 (s, 1H), 7.49-7.69 (m, 3H), 8.22, (s, 1H), 13.25 ppm
(s, 1H);

13

C NMR (126 MHz, DMSO-d6) δ 15.85, 41.77, 55.92, 65.44, 97.97, 101.46,

106.68, 107.78, 111.98, 112.87, 113.30, 116.25, 125.40, 128.70, 131.11, 134.12, 145.04,
155.52, 165.16, 166.57, 169.96, 180.45 ppm.
(Z)-N-(1-((2-((1-ethyl-5-methoxy-1H-indol-3-yl)methylene)-3-oxo-2,3dihydrobenzofuran-6-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)-5-(2oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide

O

O

H
N
HN

S

N
H

O

O

O

O
NH

O
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(6d). To a 5 mL vial

O

O

O
N

containing 28 mg (0.072 mmol, 1.2 eq) of (Z)-2-((2-((1-ethyl-5-methoxy-1H-indol-3yl)methylene)-3-oxo-2,3-dihydrobenzofuran-6-yl)oxy)acetic acid (6c) in 300 μL of DMF
was added 18 mg (0.096 mmol, 1.6 eq) of EDC (N-(3-Dimethylaminopropyl)-N′ethylcarbodiimide) under stirring at 0 oC. After 20 min, 25 mg (0.06 mmol, 1 eq) of EZLink® Amine-PEGn-Biotin (Thermo Scientific, MA USA) was added. The mixture was
stirred for 24 hours at room temperature, extracted with DCM, washed with brine, dried
and purified on preparative silica plates by 1:13 methanol: dichloromethane (Rf = 0.28) to
afford 20 mg (42%) of 6d as yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 1.23-1.6 (m,
9H), 2.02-2.06 (t, 2H), 3.85 (s, 3H), 2.54-2.57(d, 1H), 2.77-2.81 (dd, 1H), 3.0 (m, 1H),
3.14-3.5 (m, 16H), 4.10-4.11 (m, 1H), 4.26-4.32 (m, 3H), 4.69 (s, 2H), 6.35 (s, 1H), 6.40
(s, 1H), 6.88-7.70 (m, 7H), 7.80-7.83 (t, 1H), 8.21 (s, 1H), 8.22-8.25 ppm (t, 1H);

13

C

NMR (126 MHz, DMSO-d6) δ 15.82, 25.68, 28.46, 28.62, 35.50, 38.83, 41.78, 55.85,
55.93, 59.58, 61.44, 67.74, 69.23, 69.57, 69.95, 70.0, 70.1, 98.23, 101.51, 106.78, 107.80,
111.99, 113.04, 113.30, 116.33, 125.37, 128.67, 131.14, 134.13, 145.00, 155.53, 163.12,
165.03, 166.52, 167.36, 172.54, 180.47 ppm.
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Biology

The alpha-tubulin antibody was from GeneTex, Inc. (USA). The beta-tubulin antibody was
from Developmental Studies Hybridoma Bank (Iowa city, IA USA). RO3306 was
purchased from Cayman Chemical (Ann Arbor, MI, USA). TRITC-conjugated anti-rabbit
antibody, DAPI and PI (propidium iodide) were from ThermoFisher (USA).

Cell lines and cell culture
PC-3, MCF-7, LS174T, HEK-293T and A549 cells were cultured in the medium
recommended by American Type Culture Collection at 37 ̊C with 5% CO2 atmosphere in
a water jacketed incubator (NuAire). Ovcar-8 and NCI/ADR-RES cells were gifts from Dr.
Markos Leggas, University of Kentucky, Lexington, KY USA.
Cell proliferation inhibition assay
Cancer cells were seeded into 24-well plates at a density of 20,000 cells per well in
1 mL of culture medium and were cultured overnight at 37 ̊C. Compounds and the vehicle
control (DMSO) were added to the cells. After 6 days, the medium was removed, and 100
µL of trypsin was added. The cells were re-suspended in phosphate-buffered saline (PBS)
and were counted by Vi-CELL XR 2.03 (Beckman Coulter, Inc. USA). The ratio R of the
number of viable cells in the compound treatment group to the number of viable cells in
DMSO treatment group was taken as relative growth, and the percentage growth inhibition
was calculated as (1-R)*100. For initial testing, compounds were added to the cells at a
final concentration of 10 µM. Active compounds at 10 µM were tested at lower
concentrations than 10 µM.
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Biotin-streptavidin pull-down assay

PC-3 cell lysates were collected and precleaned by incubation with 50 μL of
streptavidin mag sepharoseTM (GE Healthcare Bio-Sciences, Uppsala, Sweden) under
shaking at 4 ̊C for 3 hours. Then the lysate was divided in two tubes. To the control tube,
DMSO and 10 μL of streptavidin mag sepharoseTM were added and to the binding reaction
tube, compound 6d and 10 μL of streptavidin mag sepharoseTM were added. The two
mixtures were incubated under shaking at 4 ̊C for 3 hours and washed with PBS for 4 times.
The obtained samples were diluted with 2x loading buffer, boiled at 100 ̊C for 3 minutes,
and resolved by 10% SDS-PAGE gel.
Silver staining
Silver staining was done following a published procedure39.
NCI-60 cell lines
The lead compound aurone 5a was submitted to the National Cancer Institute
(Rockville, MD, USA) to test in the NCI-60 cell lines using cell proliferation inhibition
assay.
Immunofluorescence imaging
Tubulin networks were examined by confocal immunofluorescence imaging.
Briefly, PC3 cells were placed at a density of 80,000/mL to 24-well plates equipped with
round microscope glass cover slides. After culturing at 37 ̊C for 24 hours, DMSO or
compounds were added to the cells and incubated for additional 6 hours. Then the medium
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was removed and the cells were washed with PBS three times. Primary anti-α-tubulin
antibody was added and incubated overnight at 4 ̊C. After additional washing, secondary
TRITC-conjugated anti-rabbit antibody was added for 40 min, followed by additional
washing and staining with DAPI. Final washing was performed and the cover slides were
inverted onto glass slides. Images (40x) were taken using a Nikon confocal microscope
with excitation at 557 nm and emission at 576 nm.

In vivo microtubule assembly assay
The amount of insoluble polymerized microtubules and soluble tubulin dimers in
cells after exposure to aurones were detected using a reported method. Cells were seeded
in 6-well plates at 50% confluency and cultured overnight. DMSO or aurones in DMSO
solution were added, and the cells were incubated for additional 6 hours. The medium was
removed, and cells were washed with PBS three times followed by the addition of a lysis
buffer prepared from 20 mM Tris-HCl (pH 6.8), 1 mM MgCl2, 2 mM ethylene glycolbis(β-aminoethyl ether) (EGTA), 20 µg/mL aprotinin, 20 µg/mL leupeptin, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 1mM orthovanadate , and 0.5% NP40. The lysates
were centrifuged at 12,000 g for 10 min to obtain supernatants and pellets that were mixed
with loading buffer and heated to 100 oC. Standard western blotting against α-tubulin was
performed as described previously40.

In vitro tubulin polymerization assay
An in vitro tubulin polymerization assay was performed using a protocol from
Cytoskeleton, Inc. (Denver, CO USA). Tubulin powder (Cytoskeleton Inc. Denver, CO
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USA) was dissolved in a buffer prepared from 100 mM PIPES (pH 6.9), 2 mM MgCl2, 1
mM GTP, and 5% glycerol at 0oC. Aliquots (80 µL, 3.75 µg/µL) of this tubulin solution
were divided into the wells of a 96-well half-area plate (Corning Inc., NY USA). After
adding either DMSO or testing compounds, the plate was mounted on a Spectra MRTM
microplate spectrophotometer equipped with a thermal controller at 37 ̊C (Dynex
Technologies, Inc., Chantilly, VA USA). Readings at 350 nm were recorded every 30 s for
1 hour.

Molecular docking studies
An X-ray crystal structure of αβ-tubulin binding with colchicine (pdb: 4O2B) was
downloaded from RCSB Protein Data Bank and manipulated using AutoDockTools-1.5.6
(Molecular Graphics Laboratory, The Scripps Research Institute, La Jolla, CA 92037
USA).The αβ-Tubulin dimer was separated from 4O2B using PyMOL (Version 1.7.4.5
Edu). Water molecules were removed, and polar hydrogens and Kollman charges were
added. The docking pocket (colchicine-binding site) was defined as follows: Search space:
18 x 18 x 18 Å3; Center_x, y, z = 14.815, 9.422, - 20.186. The aurones 4d, 5a, and
colchicine were manipulated by Openbabel. Molecular docking of 4d, 5a, and colchicine
to the colchicine-binding site was executed using AutoDock vina-1.1.2 using the iterated
gradient-based local search method with a Broyden–Fletcher–Goldfarb–Shanno (BFGS)
method for local optimization41. Exhaustiveness was set at 14 and the number of modes
was nine. Other parameters were left at default values.
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Competitive tubulin binding assay
A competitive, tubulin-binding assay42 was performed as described to demonstrate
that aurones bound to the colchicine-binding site of tubulins. The colchicine quantification
was performed at the University of Kentucky Proteomics Core using a protocol modified
from a previously published method. Liquid Chromatography-Electrospray IonizationTandem Mass Spectrometry (LC-MS/MS) analysis was carried out using a TSQ Vantage
mass spectrometer (Thermo Fisher Scientific, Waltham, MA USA) coupled with a
Shimadzu high performance liquid chromatography (HPLC) system (Shimadzu Scientific
Instruments, Inc., Columbia, MD USA) through an electrospray ionization source. The
colchicine-containing samples were separated with a Kinetex® reversed phase 2.6 μm XBC18 100Å LC column (100 x 4.6 mm) (Phenomenex Inc., Torrance, CA USA) at a flow
rate of 300 μL/min. Mobile phase A was water with 0.1% (v/v) formic acid while mobile
phase B was acetonitrile with 0.1% (v/v) formic acid. A 16 min gradient condition was
applied: initial 60% mobile phase B was increased linearly to 100% in 3 min, remained
100% for 3 min, and quickly (0.01min) decreased to 60% for re-equilibration. Multiple
reaction monitoring (MRM) mode was used to scan from m/z 400 to m/z 310 in the positive
mode to obtain the most sensitive signals for colchicine. The spraying voltage was set at
4000 V, vaporize temperature at 300 °C, capillary temperature at 350 °C and sheath gas
pressure at 45 (arbitrary units). Collision energies (CE) were set at 25 volts. Xcalibur
software (Ver. 2.1.0, Thermo Fisher Scientific, Waltham, MA USA) was used for the data
acquisition and quantitative processing. A series of colchicine at concentrations of 20, 40,
80, 200, 400, 800 nM were prepared to establish a linear calibration curve with a coefficient
of correlation R2 = 0.9944.
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Cell cycle assay by flow cytometry
Briefly, a million of PC-3 cells were placed in 6-cm dishes and cultured at 37 ̊C for
24 hours. DMSO or compounds in DMSO were added to the cells and incubated for
additional 16 hours. The cells were trypsinized, washed with ice cold PBS twice, and
resuspended in 500 μL of PBS. This cell suspension was added to 5 mL of 70% ethanol
dropwise in a 15 mL tube that was placed on vortex and kept at -20 ̊C overnight. The cells
were further washed with PBS and 2 μL of 50 mg/ml RNase (final 0.2 mg/ml) and 2.5 μL
of 4 mg/mL PI (final 20 μg/mL) were added. The mixture was incubated at dark for 45 min
and filtered through 35 μm nylon mesh for analysis by the Flow Cytometry and Cell Sorting
Shared Resource Facility of the University of Kentucky Markey Cancer Center.
hERG binding studies
An HEK-293 cell line stably expressing the hERG potassium channel (accession
number U04270) referred to as hERG-HEK cells were received at passage 11 (P11) from
Millipore (CYL3006, lot 2, Billerica, MA USA). [3H]-Dofetilide (specific activity of 80
Ci/mmol; labeled on the N-methyl group) was obtained from American Radiolabeled
Chemicals, St. Louis, MO USA). Other chemicals and solvents were obtained from SigmaAldrich (Milwaukee, WI USA) with exceptions of polyethylenimine (PEI), which was
obtained from Fluka/Sigma-Aldrich (St. Louis, MO USA), and Minimum Essential
Medium (MEM) with GlutaMAXTM and phenol red, MEM non-essential amino acids
solution (NEAA, 100X), G418 disulfate salt solution, fetal bovine serum (FBS), 0.05%
Trypsin-Ethylenediaminetetraacetic acid (EDTA) 1X with phenol red, and Hank’s
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balanced salt solution (HBSS), which were obtained from Life Technologies (Carlsbad,
CA USA).
hERG-HEK Cell Culture
The hERG-HEK cells were cultured according to the protocol provided by Merck
Millipore (Burlington, MA USA). Cells were maintained in MEM (with glutamax and
phenol red) supplemented with 10% FBS, 1% NEAA and 400 g/ml geneticin, and
incubated at 37 °C in a humidified atmosphere with 5% CO2. Frozen aliquots of cells were
transferred into T-75 cm2 flasks and allowed to adhere for 4-8 hours. The medium was
replaced every 2 days. Passages were carried out at least 3 times after thawing at 6 day
intervals. Cells were dissociated with trypsin/EDTA and seeded into new 150 x 25 mm
dishes at 2-3 x 106 cells per dish and placed at 30 °C, 5% CO2, for 40-48 hours prior to
membrane preparation. Membrane preparation occurred 6 days after the last passage
(passage 20).
[3H]-Dofetilide binding assay
Membrane preparation
Cell membrane preparation was based on previous methods43-45. Cells were rinsed
twice with HBSS at 37 °C and collected by scraping the dishes in ca. 20 mL of ice-cold
0.32 M sucrose and homogenized on ice with a Teflon pestle using a Maximal Digital
homogenizer (Fisher Scientific, Pittsburgh, PA USA) at ~280 rpm for 30 sec. Homogenates
were centrifuged at 300g and 800g for 4 min each at 4°C. Pellets were resuspended in 9
mL of ice-cold Milli-Q water and osmolarity restored by addition of 1 mL of 500 mM Tris
buffer (pH 7.4) followed by suspension and centrifugation at 20,000g for 30 min at 4°C.
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Pellets were homogenized in 2 mL assay buffer (50 mM Tris, 10 mM KCl, and 1 mM
MgCl2, 4°C) and aliquots of cell membrane suspensions were stored at -80°C and thawed
the day of the [3H]-dofetilide binding assay. Protein content was determined prior to the
assay using a Bradford protein assay with bovine albumin as the standard.
[3H]-Dofetilide binding assay
[3H]-Dofetilide binding assays using hERG-HEK293 cell membranes were based
on previous methods. Assays determining concentration-response were performed in
duplicate, and three independent assays were performed for each analog evaluated. Cell
membrane suspension (5 μg) was added to duplicate tubes containing assay buffer, 25 μL
of a single concentration of FIDAS agent (concentration range of 10 nM-100 µM for each
experiment), and 25 μL of [3H]-dofetilide (5 nM, final concentration) for an assay volume
of 250 μL. Binding occurred for 60 min at 25oC and was terminated by rapid filtration
through Whatman GF/B filters, which were pre-soaked in 0.25% PEI overnight, using a
Brandel cell/membrane harvester (M-48; Brandel Inc., Gaithersburg, MD USA). Filters
were washed three times with ca. 1 mL of ice-cold assay buffer. Radioactivity was
determined by liquid scintillation spectrometry using the Tri-Carb 2100-TR Liquid
Scintillation Analyzer (Perkin-Elmer Life and Analytical Sciences).
In vivo evaluation of anti-leukemia activity in the zebrafish model
Zebrafish studies were carried out with approval from the Institutional Animal Care
and Use Committee of the University of Kentucky (2015-2225). All methods were
performed in accordance with the relevant guidelines and regulations governing research
protocols involving animals. Rag2: myc-GFP zebrafish (n=8) at 21 days of age were
44

treated with DMSO, either aurones 5a or 5r in 1.5 mL of fish-system water in 12-well
plates. Zebrafish were treated with compound for 2 days, removed from drug for 1 day,
and treated for two more days with freshly prepared solutions of compound. Animals were
imaged at the start and end of treatment using a fluorescence-equipped dissecting
microscope at 350 ms exposure. The GFP image was overlaid onto the bright-field image
of each animal in Photoshop, and the percent change in leukemia burden was calculated
by normalizing the GFP+ area to the total area of the animal in ImageJ (National Institute
of Health, USA).
In vivo evaluation of antineoplastic activity and gross toxicity in PC-3 xenografts
Mouse studies were carried out with approval from the Institutional Animal Care
and Use Committee of the University of Kentucky (2009-1064). All methods were
performed in accordance with the relevant guidelines and regulations according to
protocols. PC-3 cells suspended in PBS were subcutaneously injected in the lower flanks
of immune-deficient nude mice (5 mice in each group, two tumors on each mouse) at a
density of 2 x 106 cells in 200 µL of PBS. After tumors were established (in about two
weeks), aurone 5a formulated in a mixture of Tween-80 (5%), DMSO (10%), PEG400
(25%) and PBS (60%) was intraperitoneally administered to mice at a daily dose of 10 mg
of aurone 5a/kg (mouse). The first day of treatment was set as day 1. At day 18 treatment
was ceased and mice were sacrificed. Blank vehicle was used as a control. Tumors and
mouse weights were measured, and tumor volumes were calculated as Length x width2/2.

Statistics
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Biological assays have been performed at least twice. Data were shown as mean ±
SD or the 95% confidence intervals were provided. For the mice study, five mice with two
tumors on the lower flanks of each mouse were used in each treatment group. The data for
the mouse study were analyzed by t-test. For the zebrafish study, eight fish were used in
each treatment group.
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Chapter 3 Structure-activity relationships of semisynthetic aurones
Introduction
Published studies of structure-activity relationships (SAR) in aurones as
antineoplastic agents replaced the C-2 phenylmethylene subunit (i.e., so-called
“benzylidene” subunit) found in many naturally occurring aurones, such as sulfuretin (1a)
and aureusidin (1b) (Figure 3.1 A), with a C-2 heteroarylmethylene group. For example,
benzofuran-3(2H)-ones with 2-(coumarin-4-yl)methylene46 groups or 2-(furan-2yl)methylene47 groups displayed in vitro activity against human leukemia K562 cells;
benzofuran-3(2H)-ones with 2-(piperazin-1-yl)methylene groups possessed IC50 values in
the low micromolar range against various solid tumor cell lines48; and benzofuran-3(2H)ones with 2-(indol-3-yl)methylene groups inhibited cell proliferation in breast cancer
MCF-7 and MDA-MB-231 cell lines49. Another published study reported aurone (2Z)-2benzylidene-4-hydroxy-6-methoxy-1-benzofuran-3(2H)-one as a P-glycoprotein inhibitor,
and this compound modulated P-glycoprotein-mediated multiple drug resistance as an
indirect antineoplastic agents50. The 4’ position of benzylidene was replaced by different
halogens that resulted in different binding affinities to P-glycoprotein. Substitutions of the
C-6 position of benzofuran-3(2H)-one have not been explored thoroughly for
antineoplastic purposes. In addition, the relative potencies among these different C-2
heteroarylmethylene-substituted aurones were in the micromolar range. The in vivo activity
of these aurones, and the specific biological target or targets in these cases were unclear.
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In this chapter, we will discuss modifications that were made on the C-6 and C-2
positions of benzofuran-3(2H)-one to generate novel aurone analogs. Iterative synthesis
and proliferation inhibition assays using PC-3 cells were used to determine the relative
proliferation inhibition compared to the vehicle control, dimethyl sulfoxide (DMSO).
Results

Figure 3.1: A, Representative, naturally occurring aurones, sulfuretin (1a) and
aureusidin (1b). B, Synthesis of aurones 3-5. Legend: a, heterocyclic-substituted
benzaldehydes or heteroarylcarboxaldehydes, 50% aq. potassium hydroxide, 1:1
ethanol: N,N-dimethylformamide, b, bromoacetonitrile, potassium carbonate, N,Ndimethylformamide; c, halogenated benzyl bromide, potassium carbonate, N,Ndimethylformamide. C, Leading aurone candidate. (Z)-2-((2-((1-ethyl-5-methoxy1H-indol-3-yl) methylene)-3-oxo-2,3-dihydrobenzofuran-6-yl) oxy) acetonitrile
(5a).

Synthesis of semisynthetic aurones modified at C-2
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Modifications of aurones were investigated in which either we attached a
heterocyclic ring to the C-2 phenylmethylene group as in aurones 3 or we replaced the
entire C-2 phenylmethylene group with a C-2 heteroarylmethylene group as in aurones 4
(Figure 3.1 B). The syntheses51 of 6-hydroxyaurones 3 and 4 involved the condensations
of 6-hydroxybenzofuran-3(2H)-one (2) with heterocyclic-substituted benzaldehydes and
heteroaryl carboxaldehydes, respectively (Figure 3.1 B). Although literature reports
described various catalysts52-57 for similar condensations, we found that the use of 50%
aqueous potassium hydroxide (2 eq) in 1:1 ethanol-N,N-dimethylformamide (DMF)
furnished the 6-hydroxyaurones 3 and 4 in good yields. (Z)-Stereochemistry was in accord
with prior acid or base-catalyzed condensations of benzofuran-3(2H)-ones with aromatic
aldehydes50,58. A reiterative process of synthesis and screening using in vitro prostate
cancer PC-3 cell proliferation assays identified 4-(pyrrolidin-1-yl)phenylmethylenesubstituted aurone 3a and heteroarylmethylene-substituted aurones 4d, 4e, 4g and 4l with
1-isoquinolyl, 2-quinolyl, 8-methoxy-2-quinolyl, and 5-methoxy-N-ethyl-3-indolyl groups,
respectively, as the most potent analogs at 10 µM concentrations (Table 1). Only the latter
heteroarylmethylene-substituted aurones 4 retained any activity at concentrations below 10
µM.

Comparable outcomes were observed using in vitro colorectal LS174T cell

proliferation assays with the exception of aurone 3a that showed no appreciable activity in
this cell line even at 10 µM concentration (data not shown for C-4 hydroxyl groups or C-7
methyl groups) failed to produce analogs with improved activity relative to their
unsubstituted counterparts (data not shown). Among the heteroarylmethylene-substituted
aurones 4, the 3-indolylmethylene-substituted aurone 4l warranted additional study based
on a combination of modest potency in cell proliferation assays in the 1-10 µM range.
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Table 1. Abbreviated SAR study involving modifications aurone at the C-2 and C6 positions using prostate cancer PC-3 cell proliferation assays
Inhibition of
PC-3 Cells

Aurone

Ar1

3a
3b

4-(pyrrolidin-1-yl)phenyl
4-(morpholino-1-yl)phenyl
4-(4-methylpyridazin-1yl)phenyl
2-pyridyl
3-pyridyl
4-pyridyl
1-isoquinolyl
2-quinolyl
6-methoxy-2-quinolyl
8-methoxy-2-quinolyl
4-quinolyl
3-indolyl
N-methyl-3-indolyl
N-methyl-5-methoxy-3indolyl
N-ethyl-5-methoxy-3indolyl

3c
4a
4b
4c
4d
4e
4f
4g
4h
4i
4j
4k
4l

10 µM

1 µM

95±4.7
7.8±7.7

2.1±7.1

42±14
8.8±15
0
20±5.4
88±5.5
99±0.2
8.4±33
97±0.8
63±7.2
20±6.8
41±25

26±8.6

35±28

17±5.5

69±16

13±9.5

40±8.4
16±3.5

Synthesis of semisynthetic aurones modified at C-6
Alkylation of the C-6 hydroxyl group in heteroarylmethylene-substituted aurones
4 using various alkyl bromides and anhydrous potassium carbonate in N,Ndimethylformamide (DMF) led to the alkoxy-substituted aurones 5 (Figure 3.1 B). An
SAR study involving dual modifications of the C-6 alkoxy group and the C-2
heteroarylmethyelene group revealed a pattern favoring either a cyanomethoxy or a 2,650

dichlorobenzyloxy

group

at

C-6

and

favoring

one

of

the

following

C-2

heteroarylmethylene subunits: N-methyl-3-indolylmethylene, N-ethyl-3-indolylmethylene,
5-methoxy-N-methyl-3-indolylmethylene,

or

5-methoxy-N-ethyl-3-indolylmethylene

groups (Table 2). One candidate emerged with 90%+ inhibition of in vitro prostate cancer
PC-3 cell proliferation at 300 nM concentration: (Z)-2-((2-((1-ethyl-5-methoxy-1H-indol3-yl)methylene)-3-oxo-2,3-dihydrobenzofuran-6-yl)oxy)acetonitrile (5a) (Figure 3.1 C;
Table 2). Modifications at other positions (e.g., methyl groups at C-7 as in 5i and 5m) in
addition to these modifications at C-2 and C-6 led to diminished activity relative to aurone
5a.
The pairing of the cyanomethoxy group at C-6 with the (N-ethyl-5-methoxy-1Hindol-3-yl) methylene at C-2 in aurone 5a and the pairing of the 2,6-dichlorobenzyloxy
group at C-6 with the (pyridin-4-yl)methylene at C-2 in aurone 5r were essential to potency.
Alternate pairings, modification in the halogenation type and pattern in the 2,6dichlorobenzyloxy group, changes in the N-ethyl-5-methoxy-1H-indol-3-yl group (e.g.,
replacement of the N-ethyl with an N-methyl group; replacement of the 5-methoxy with a
5-hydroxy group), and modifications at still other positions in the benzofuran (e.g., methyl
groups at C-7) led to diminished activity in the prostate cancer PC-3 cell proliferation assay
relative to aurones 5a and 5r.

51

Table 2. SAR study involving modifications of the C-6 alkoxy group in aurones 5
versus modifications of the C-2 heteroaryl-substituted methylene subunit using prostate
cancer PC-3 cell proliferation assays.
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Aurone

C-6

C-7

5a

OCH2CN

H

5b

OCH2CN

H

5c

OCH2CN

H

5d

OCH2C6H4-2-F

H

5e

OCH2C6H4-2-Cl

H

5f

OCH2C6H3-2,6-F2

H

5g

OCH2C6H3-2,6-Cl2

H

5h

OCH2C6H3-2-F-6Cl

H

5i

OCH2C6H3-2,6-Cl2

CH3

5j

OCH2C6H3-2-F-4Cl

H

5k

OCH2C6H3-2-F-6Cl

H

5l

OCH2C6H3-2,6-Cl2

H

5m

OCH2C6H3-2,6-Cl2

CH3

5n

OCH2C6H4-2-F

H

5o

OCH2C6H3-2,6-Cl2

H

5p

OCH2C6H3-2-F-6Cl

H

5q

OCH2C6H3-2,6-Cl2

H

5r

OCH2C6H3-2,6-Cl2

H

C-2 Heteroaryl
Group
N-ethyl-5methoxy-3indolyl
N-ethyl-5hydroxy-3indolyl
Ncarboxymethyl5-hydroxy-3indolyl
N-methyl-3indolyl
N-methyl-3indolyl
N-methyl-3indolyl
N-methyl-3indolyl
N-methyl-3indolyl
N-methyl-3indolyl
N-methyl-5methoxy-3indolyl
N-methyl-5methoxy-3indolyl
N-methyl-5methoxy-3indolyl
N-methyl-5methoxy-3indolyl
N-ethyl-5methoxy-3indolyl
N-ethyl-5methoxy-3indolyl
N-ethyl-3indolyl
N-ethyl-3indolyl
4-pyridyl
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Inhibition of PC-3 Cells
1 µM

300
nM

95±2.5

93±2.8

96±2

24±11

96±1.4

80±8

28±4.4

31±40

0

10 µM

96±1.6

0
0
20±6.6
82±4.3

7±35
8.6±12
57±18
96±1.8

82±7.7

24±7.3

0
52±23

28±15

96±1.1

67±5.8

3.9±11

95±4.4

91±2.2

44±5.6

97±0.6

98±1

75±7.7

92±0.4

95±1.1

Aurones 5a and 5r showed broad antineoplastic activities
In addition to the prostate cancer PC-3 cell line in which aurone 5a displayed an
IC50 of 57.8 ± 1.1 nM, I determined that aurone 5a displayed inhibition of colorectal cancer
LS174T, lung cancer A549, breast cancer MCF-7, and ovarian cancer Ovcar-8 and
NCI/ADR-RES cell lines with IC50 values in the low to mid-nanomolar range (Table 3).
During a five-day treatment period, aurone 5a showed potent, dose-dependent in vitro
inhibition of these cancer cell lines. Treatment of a normal human embryo lung cell line
HEL299 with aurone 5a showed an IC50 in the micromolar range (1.3 ± 0.2 μM), a finding
that suggested aurone 5a was selectively more toxic to cancer cell lines than normal cell
lines.

Table 3. IC50 values of aurones 5a and 5r in cancer cell line proliferation inhibition assays

Cell lines
PC-3
LS174T
A549
MCF-7
NCI/ADR-res
OVCAR-8

Aurone 5a
58.7±1.1
155.2±1.1
173.6±1.0
244.3±1.2
85.9±1.0
181.9±1.0

IC50 (nM)

Aurone 5r
66.0±1.1
158.3±1.0
113.0±1.0
185.6±1.1
190.3±1.1
257.7±1.1

Discussion
Previous SAR of aurones as antineoplastic agents focused on the substitution of the
C-2 position of the benzofuran-3(2H)-one subunit and generated a number of aurone
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analogs with limited potencies in the micromolar range46-50. The mechanisms of action of
those aurone analogs were unclear, and the in vivo efficacy was not evaluated. Hence,
further efforts were needed to improve the potency of aurone analogs. A reiterative process
of synthesis and testing was used to guide the development of SAR relationships within
the aurone pharmacophore. Aurones in which the C-2 position had either a heterocyclicsubstituted phenylmethylene group as in aurone 3 or a heteroarylmethylene group as in
aurone 4 (Figure 3.1 B) were examined. Using in vitro inhibitory activity in prostate cancer
PC-3 cell proliferation assay as a readout, we established that the aurones 4 bearing either
1-isoquinolyl, 2-quinolyl, 8-methoxy-2-quinolyl, or 5-methoxy-N-ethyl-3-indolyl groups
were more potent than most aurones 3 at 10 µM concentrations (Table 1). Modifications
of the benzofuran-3(2H)-one subunit in these heteroarylmethylene aurones 4 at other
positions failed to produce aurones with improved activity relative to the
heteroarylmethylene-substituted aurones 4d, 4e, 4g and 4l (Table 1).
The alkylation of the C-6 hydroxyl group in 3-indolylmethylene-substituted
aurones 4 with various alkyl bromides secured the C-6 alkoxy 3-indolylmethylenesubstituted aurones 5 (Figure 3.1 B). An SAR study involving modifications of the C-6
alkoxy group in concert with the 3-indolylmethyelene subunit at C-2 revealed a synergistic
effect favoring either a C-6 cyanomethoxy or a 2,6-dichlorobenzyloxy group and one of
the following C-2 heteroarylmethyelene subunits: N-methyl-3-indolylmethylene, N-ethyl3-indolylmethylene; 5-methoxy-N-methyl-3-indolylmethylene or 5-methoxy-N-ethyl-3indolylmethylene (Table 2). One candidate displayed significant inhibition (IC50 58 ± 1.1
nM) on the in vitro proliferation of prostate cancer PC-3 cells: (Z)-2-((2-((1-ethyl-5methoxy-1H-indol-3-yl)methylene)-3-oxo-2,3-dihydrobenzofuran-6-yl)oxy)acetonitrile
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(5a) (Figure 3.1 C). Alkoxy groups other than the C-6 cyanomethoxy or 2,6dichlorobenzyloxy groups possessed less activity than that of aurone 5a and 5r.
Modifications of these C-6 cyanomethoxy- or 2,6-dichlorobenzyloxy-substituted 3indolylmethylene-substituted aurones 5 with substituents at still other positions in the
benzofuran-3(2H)-one pharmacophore (e.g., C-7 methyl groups as in 5i and 5m) also led
to diminished activity in a prostate cancer PC-3 cell proliferation assay. Finally, although
we focused our studies (Table 2) on heteroaryl-substituted aurones 5 in which the indo-3ylmethylene was the preferred heteroaryl group, we examined other heteroaryl substituents
and identified only one candidate, namely (Z)-6-((2,6-dichlorobenzyl)oxy)-2-(pyridin-4ylmethylene)benzofuran-3(2H)-one (5r), that possessed a 4-pyridylmethylene group in
place of the indo-3-ylmethylene group and that displayed nanomolar potency in cell
proliferation assays.
In contrast to previous SAR of aurones that focused on the modification of C-2
position of the benzofuran-3(2H)-one subunit, we simultaneously substituted both C-6 and
C-2 positions of the benzofuran-3(2H)-one subunit, which proved to be successful to
improve the potency of aurones. The two leading aurone analogs 5a and 5r displayed
subnanomolar activities toward a panel of cancer cell lines, demonstrating broad
antineoplastic scope. The improved potency would benefit subsequent studies of
mechanism of action and biological target(s) of these aurones, and in vivo studies.
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Chapter 4 Mechanism of action of semisynthetic aurones
Introduction
Identifying the biological target(s) and understanding the mechanism of action of a
bioactive compound is both challenging and important in drug discovery and
pharmacological studies. Without the knowledge of a compound’s target(s), improving a
compound’s physical properties and efficacy by iterative chemical synthesis and testing is
not straightforward and is very time-consuming. It is also difficult to predict possible
toxicities of a compound without knowing the compound’s target(s). Therefore, different
approaches for elucidating drug targets were developed and can be classified into three
categories59: direct biochemical methods, genetic methods, and computationally based
methods.
Direct biochemical strategies rely on affinity binding between a compound and the
protein target(s). Often a compound is chemically modified with biotin or photoactive
groups to generate a bioactive probe that binds to a target and allows target purification or
detection. Although the workflow for affinity-based target identification is straightforward,
it is often difficult to generate a bioactive probe by chemically perturbing the original
leading compound.
Unlike direct biochemical target identification, genetic-based methods do not
require the chemical modification of the compound of interest. Instead, genetic-based
methods utilize recent advances in molecular biology, including large-scale geneperturbation and genomic measurements. The combination of small interfering RNA
(siRNA)60 or clustered regularly interspaced short palindromic repeats (CRISPR)61
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libraries targeting the whole exome in mammalian cells and sub-lethal concentrations of a
compound to enrich resistant cell colonies followed by next generation DNA sequencing
would generate direct target(s) or target signaling pathways.
Computational methods have also been developed for uncovering biological targets
for small molecules. One of the early examples is the NCI COMPARE algorithm62 from
the National Cancer Institute (NCI). This algorithm leverages the idea that compounds that
have similar mechanism of action should show similar dose-responses in a similar assay.
The National Cancer Institute has determined the growth-inhibition profiles of more than
88,000 pure compounds and more than 34,000 crude extracts against the NCI-60 cancer
cell line panel consisting of 60 human cancer cell lines. A compound with unknown target(s)
is first tested against the NCI-60 cancer cell line panel and considered as a “seed”. The NCI
COMPARE ranks the entire database of tested compounds in the order of similarity of the
responses of the NCI-60 cell lines to the compounds in the database to the responses of the
cell lines to the “seed compound”. The similarity is quantified as a Pearson correlation
coefficient and highly ranked compounds may share a similar mechanism of action to the
seed compound. For example, the leading compound, namely aurone 5a, was submitted to
NCI for testing in the NCI-60 cancer cell line panel.

Results
Attempted affinity-based approach to purify aurone 5a’s binding partner

58

According to the structure-activity relationships that were discussed in the previous
chapter, a biotinylated aurone 6d was designed and synthesized using a multi-step
procedure (Figure 4.1). This analog 6d was tested in PC-3 cell proliferation assay and
showed growth inhibitory activity at 10 and 30 µM (Figure 4.2), values that were judged
to be sufficient for an effective probe in a pull-down assay.

Figure 4.1: Synthesis scheme of biotinylated aurone analog 6d. a, 1-ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC).
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A streptavidin and biotin-based pull-down was performed using PC-3 cell lysates,
and the results were visualized in by silver staining an SDS-PAGE gel (Figure 4.5), but
unfortunately, this procedure did not reveal any targets. A possible reason why an active
biotinylated probe did not pull down anything was that the binding site was at the interface
of two protein monomers (in our case, tubulin alpha and beta monomers), so that the
binding of biotinylated probe to the interface would destabilize the protein dimer.

Normalized cell
growth to DMSO

120.0

100.0

90.0
59.5

60.0
30.0
0.0

10.6
DMSO

1.9

5a-300 nM 6d-30 μM 6d-10 μM

Figure 4.2: Biotinylated aurone analog 6d inhibited PC-3 cell growth.
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Figure 4.3: pull-down assay results. Left lane, DMSO; Right lane, biotinylated
aurone analog 6d.

Use of NCI COMPARE analysis
As noted above, the leading compound, aurone 5a, was submitted to NCI for testing
in the NCI-60 cancer cell line panel using cell proliferation inhibition assay. Results appear
in Table 4. The majority of cancer cell lines in the NCI-60 panel were sensitive to aurone
5a, and the data agreed well with the IC50 values of aurone 5a in Table 2.
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Table 4. IC50 values of aurone 5a in NCI-60 cell line proliferation inhibition assays (Data
generated by the National Cancer Institute (Maryland, USA)).
Panel/Cell Line
Leukemia
CCRG-CEM
HL-60(TB)
K-562
MOLT-4
RPMI-8226
SR
Non-Small Cell
Lung Cancer
A549(ATCC)
EKVX
HOP-62
HOP-92
NCI-H226
NCI-H23
NCI-H322M
NCI-H460
NCI-H522

GI50 (nM)
289
236
212
523
352
275
GI50 (nM)
5.1 µM
2.73 µM
542
NA
57.4 µM
812
1.43 µM
337
3.13 µM

Colon Cancer
COLO 205
HCC-2998
HCT-116
HCT-15
HT29
KM12
SW-620

GI50 (nM)
446
3.44 µM
386
399
356
546
345

CNS Cancer
SF-268
SF-295
SF-539
SNB-19
SNB-75
U251

GI50 (nM)
848
307
269
468
5.65 µM
453

Prostate Cancer
PC-3
DU-145

GI50 (nM)
367
643
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Panel/Cell Line
Melanoma
LOX IMVI
MALME-3M
M14
MDA-MB-435
SK-MEL-2
SK-MEL-28
SK-MEL-5
UACC-257
UACC-62

GI50 (nM)
696
> 100 µM
319
174
836
10.2 µM
405
67.1 µM
499

Ovarian Cancer
IGROV1
OVCAR-3
OVCAR-4
OVCAR-5
OVCAR-8
NCI/ADR-RES
SK-OV-3

GI50 (nM)
774
377
19 µM
2.52 µM
483
406
669

Renal Cancer
786-0
A498
ACHN
RXF 393
SN 12C
TK-10
UO-31

GI50 (nM)
470
10.3 µM
794
182
763
56.9 µM
864

Breast Cancer
MCF7
MDA-MB-231
HS 578T
BT-549
T-47D
MDA-MB-468

GI50 (nM)
311
2.66 µM
360
571
NA
2.16 µM

NCI COMPARE analysis was used to explore possible mechanisms of action. The
results are summarized in Table 5. The highly ranked compounds were tubulin inhibitors,
and this finding first suggested that aurone 5a was a tubulin inhibitor.
Table 5. Results of the NCI COMPARE analysis.

Rank

Correlation

NCI compounds

1

0.789

NSC S736992

2

0.78

NSC S736359

3

0.769

NSC S31708

4

0.736

NSC S330770

5

0.728

NSC S123528

6

0.728

NSC S650770

Disruption microtubule networks
As described in Chapter 1, tubulins polymerize into microtubules that are key
components of the cell cytoskeleton. To test whether aurone 5a and 5r affected microtubule
networks and cell morphology, studies of immunofluorescence imaging against alpha
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tubulin were carried out, and as shown in Figure 4.4, the control, namely DMSO-treated
cells, retained their normal microtubule network and an overall, shuttle-like morphology
(Figure 4.4 A). On the other hand, aurone 5a and 5r-treated cells demonstrated significant
microtubule depolymerization and adopted a round morphology (Figure 4.4 B, C, D, E).
These results supported, but did not prove, the conclusion that aurone 5a and 5r were
tubulin inhibitors.
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Figure 4.4: Aurone 5a and 5r treatment (6 hours) inhibited microtubule structures and caused
cell morphology change in PC-3 cells as shown in panels A, DMSO; B, 5a (1 µM); C, 5a
(300 nM); D, 5r (1 µM); E, 5r (300 nM). Red immunofluorescence: α-tubulin; blue: DAPI.
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Effects on cell cycle
Because microtubules are the most abundant components of the mitotic spindle, a
study of the effect of aurones 5a and 5r on cancer cell mitosis was warranted. Treatment
of PC-3 cells with aurones 5a and 5r, and an analysis of the cell cycle by flow cytometry
was performed. Compared to DMSO (Figure 4.5), aurones 5a and 5r induced significant
cell cycle arrest to G2/M phase. These data again supported that aurones 5a and 5r inhibited
tubulin polymerization.
Tubulin polymerization in vivo and in vitro
To further test whether aurone 5a and 5r were tubulin inhibitors, in vivo and in vitro
tubulin polymerization assays were performed to investigate the level of tubulin
polymerization in the presence or absence of aurones 5a and 5r.
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Figure 4.5: Aurones 5a and 5r induced cell cycle arrest in PC-3 cells.
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For the in vivo tubulin polymerization assay, HEK293T cells were treated with
aurone 5a and 5r at indicated concentrations (Figure 4.6). After cell treatment and lysis,
cell lysates were separated by centrifugation into supernatants and pellets, which were
individually subjected to western blotting using antibodies against β-tubulin. The idea
behind this assay was that microtubules were “heavy” structures that would be in the pellets
after centrifugation. After treatment with aurones 5a and 5r for 6 hours, the amount of
tubulin in pellets was significantly less than that in cell lysates from DMSO-treatment alone,
even at a concentration as low as 300 nM (Figure 4.6).

Figure 4.6: Aurones 5a and 5r decreased tubulin polymerization in HEK293T
cells.

For the in vitro tubulin polymerization assay, a well-established tubulin inhibitor,
colchicine, was chosen as a positive control. Polymerized microtubules showing
absorbance at 340 nm were monitored in the presence of DMSO, colchicine (5 μM), or
aurone 5a (5 μM). In the presence of glycerol and guanosine triphosphate, either aurone
5a at 5 µM or colchicine at 5 µM decreased the formation of microtubules in a similar
fashion whereas a DMSO-treated control group showed, as expected, substantial tubulin
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polymerization (Figure 4.7). Overall, these results were in agreement with the data of the
NCI COMPARE analysis, the immunofluorescence imaging, and the cell cycle studies that
suggested aurones 5a and 5r were tubulin inhibitors.

Figure 4.7: Aurone 5a (5 µM) and colchicine (5 µM) inhibited tubulin
polymerization in vitro in a similar fashion.
Molecular docking analysis
Molecular docking was performed using AutoDock Vina41 to explore the possible
binding of aurone 5a to the colchicine-binding site (CBS) on αβ-tubulin heterodimers
because this site was well known to host a plethora of chemically unrelated compounds63.
A less active aurone 4d (Figure 4.8 A) than aurone 5a and colchicine were also docked into
the CBS for comparison. It was found that aurone 5a, 4d and colchicine occupied the CBS
at the interface of the α-tubulin and β-tubulin heterodimer (Figure 4.8 B). A hydrophobic
pocket formed by Ala, Ile and Leu residues from β-tubulin accommodated the hydrophobic
indole moiety of aurone 5a (Figure 4.8 C). The benzofuran-3(2H)-one and cyanomethoxy
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groups in aurone 5a participated in hydrophobic contacts with the loop T7 and helix H8 of
β-tubulin and with the loops T3, T4 and T5 from α-tubulin (Figure 4.8 C)14. In addition,
hydrogen-bonding interactions between the carbonyl oxygen of the benzofuran-3(2H)-one
and βAsn258 and hydrogen-bonding interactions between the nitrogen of the
cyanomethoxy group and αTyr224 and αGln11 provided additional binding stabilization
(Figure 4.8 D).
The indole moiety and a portion of the benzofuran-3(2H)-one in aurone 5a
superimposed well with the colchicine A and B rings (Figure 4.8 E); however, aurone 5a
did not occupy the hydrophobic pocket within β-tubulin in which the colchicine C ring
resided. Instead, aurone 5a formed contacts with loops T3, T4, and T5 of α-tubulin using
the benzofuran-3(2H)-one and cyanomethoxy groups. Additionally, a comparison of the
binding poses of 5a and 4d revealed why 5a possessed better potency than 4d. Aurone 4d
had major interactions with β-tubulin but lacked the bifurcated, hydrogen-bonding between
the nitrogen of the cyanomethoxy group and αTyr224 and αGln11 of α-tubulin. This
deficiency weakened the binding affinity of aurone 4d relative to the potent aurone 5a
(Figure 4.8 D).

Competitive binding assay showed aurones bound to the CBS site
A competitive, tubulin-binding assay42 confirmed that aurones 5a and 5r bound to
the colchicine-binding site. Aurone 5a or 5r were added at various concentrations to a
solution of α/β-tubulins (1.3 mg/mL) and colchicine (1.25 μM). Unbound colchicine was
separated from either tubulin-colchicine or tubulin-aurone complex by Amicon Ultra-0.5
mL Centrifugal Filters (30 kDa Cut-off). The level of unbound colchicine was measured
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by liquid chromatography-electrospray ionization-tandem mass spectrometry (LCMS/MS). Aurone 5a and 5r released colchicine from tubulin in a dose-dependent manner
(Figure 4.9) that definitively indicated that aurones 5a and 5r bound to the colchicinebinding site on tubulin.

71

Figure 4.8: (A) Structures of aurone 5a, aurone 4d, and colchicine. (B) Aurone 5a
bound to the colchicine-binding site (CBS) in the interface of αβ-tubulin dimers
(cyan for β, green for α). (C) Close-up view of the interaction environment of 5a
(gray sticks) and tubulin (cartoon). (D) Superimposition of 5a (gray sticks) and 4d
(magenta sticks) in the colchicine-binding site. Hydrogen bonding is represented by
yellow, dashed lines. (E) Superimposition of 5a (gray sticks) and colchicine (purple
sticks) in the colchicine-binding site.

72

Figure 4.9: Competitive tubulin binding assay with colchicine in the presence of
increasing concentrations of aurone 5a and 5r.
Synergistic effects of aurones with a cyclin dependent kinase inhibitor
The G2-to-M phase transition in the cell cycle is controlled by cdc2 (cdk1). Cdc2
is tightly regulated by cyclin association and by phosphorylation/dephosphorylation of Tyr
15 of cdc2. Phosphorylation of cdc2 at Tyr15 inactivates cdc2
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and leads to mitosis delay, while dephosphorylation of Tyr 15 promotes G2 to M phase
transition. Since aurone 5a arrested cell cycle to G2/M, it is reasonable for cancer cells to
dephosphorylate cdc2 at Tyr15 to push G2 to M phase transition as a feedback rescue upon
aurone 5a treatment.
To explore this, colon cancer LS174T cells and prostate cancer PC-3 cells were
treated with aurone 5a, and subject to western blot analysis against cdc2 Tyr15
phosphorylation. Compared with DMSO, aurone 5a treatment decreased cdc2 Tyr15
phosphorylation (Figure 4.10), which could be explained as a feedback rescue of cancer
cells upon aurone 5a treatment.

Figure 4.10: Aurone 5a induced cdc2 (CDK1) activation by decreasing
phosphorylation at tyrosine 15.
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To confirm this, a cell-permeable and selective ATP-competitive reversible
inhibitor of Cdk1, RO3306 was chosen to inhibit this feedback rescue. RO3306 shows
preference for Cdk1/cyclin B1 (Ki = 35 nM) over Cdk1/cyclin A (Ki = 110 nM), two CDK
complexes which regulate cell cycling. LS174T colon and PC3 prostate cancer cells were
treated with compounds at indicated combinations and concentrations, and relative cell
growth was determined. As shown in figure 4.11, the combination of 5a and RO3306
showed synergistic effects, indicating that the combination of tubulin inhibitors and cyclin
dependent kinase inhibitors can achieve improved antineoplastic effects.

Figure 4.11: Aurone 5a had synergistic effects with a cdc2 inhibitor RO3306
on the proliferation of LS174T colon and PC3 prostate cancer cells.
hERG inhibition
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A frequent side effect of drug candidates is the drug-induced arrhythmia because
of blocking the hERG K+ channel64. The binding between aurones and the hERG K+
channel was determined by [3H]-dofetilide binding assays in collaboration with Dr. Linda
P. Dwoskin at College of Pharmacy of University of Kentucky. The results showed that
none of tested aurones were hERG inhibitors (data not shown).

Discussion
Two types of inhibitors target tubulin microtubule dynamics: stabilizing agents,
such as paclitaxel, and destabilizing agents, such as the Vinca alkaloids and colchicine.
These agents bind tubulin subunits at well-characterized binding sites, some of which find
broad application in cancer therapeutics, including prostate cancer. Until recently, few
agents

were

known

that

targeted

the

colchicine-binding

site,

but

various

pharmacophores10,19,65-69 now appear to exhibit excellent potency and selective binding to
the colchicine-tubulin site. The impetus for developing these agents derives in part from
the continuing need for new tubulin-targeting drugs to meet the needs of patients
experiencing resistance or developing mutations that cripple the use of traditional taxol or
Vinca-based therapies. The semisynthetic aurones reported here provide a new
pharmacophore for the development of colchicine-targeting microtubule inhibitors for
cancer treatment.
The SAR study led to the identification of two potent leading compound aurone 5a
and 5r. A biotinylated aurone analog 6d was synthesized and showed inhibitory effect in a
PC-3 cell proliferation inhibition assay. However, the pull-down assay using biotinylated
aurone analog 6d did not reveal any potential target. The possible reasons why an active
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biotinylated probe did not pull down anything was that the binding site was at the interface
of two protein monomers (in our case, tubulin alpha and beta monomers).
Aurone 5a was submitted to NCI for further testing on the NCI-60 cancer cell line
panel. The NCI COMPARE analysis, a computational method for target identification, was
chosen to probe the mechanism of action of the leading compound aurone 5a. The NCI
COMPARE analysis suggested that aurone 5a is a tubulin inhibitor. This finding was
confirmed by the in vivo and in vitro tubulin polymerization assay (Figures 4.6, 4.7).
Consistent with this conclusion, aurone 5a inhibited microtubule formation, disrupted cell
cytoskeleton, and changed cell morphology shown by the immunofluorescence imaging
studies (Figure 4.4). Similarly, aurone 5a inhibited the most abundant component of mitotic
spindle and arrested the cell cycle to G2/M phase (Figure 4.5).
Knowledge about the binding site between a ligand and its biological target is
pivotal for structure-guided, rational design of compounds with improved properties
including potency and solubility. Molecular docking studies showed that aurone 5a binds
to the colchicine-binding site between the α-tubulin and β-tubulin. The indole moiety and
part of the benzofuran-3-one of aurone 5a as well as the A and B rings of colchicine
occupied a hydrophobic pocket in β-tubulin (Figure 4.8 C, E). However, aurone 5a did not
occupy another hydrophobic pocket in which the colchicine C ring normally resided.
Instead, aurone 5a interacted more with α-tubulin than β-tubulin and participated in
bifurcated hydrogen-bonding between the nitrogen of the cyanomethoxy group and
αTyr224 and αGln11 of α-tubulin (Figure 4.8 D). The relatively inactive aurone 4d failed
to form this same interaction because it lacked a cyanomethyl group.
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To confirm that aurone 5a and 5r bound to the colchicine-binding site, a
competitive tubulin-binding assay42 was performed. Aurone 5a and 5r bound to the CBS,
resulting in an increased amount of unbound colchicine (Figure 4.9). These data were
consistent with molecular docking results, and echoed the fact that the CBS would
accommodate chemically diverse compounds. Mechanistically, previous crystallography
studies show that free tubulin dimers are in a “straight” state and polymerized tubulin
dimers in microtubules are in a “curved” conformation12,14,70,71. During tubulin
polymerization, tubulin dimers structurally transitioned from a straight state to a curved
state, during which the T7 loop of β-tubulin flipped inwards into the CBS. As a mechanism
of action, colchicine bound to the CBS, prevented the T7 loop flipping towards the CBS,
and thus inhibited tubulin polymerization12,16. Importantly, our leading compounds showed
strong interaction with T7 loop (Figure 4.8 C, E) and reflected a similar mechanism of
action seen with colchicine. As a result, aurone 5a strongly inhibited cell cycle progression
at G2/M phases (Figure 4.5) and disrupted microtubule networks in PC-3 cells (Figure 4.4).
In cell cycle, G2 to M phase transition is controlled by cdc2 (cdk1), which is tightly
regulated by association with different kinds of cyclins, phosphorylation status of Tyr 15
of cdc2. Phosphorylation of cdc2 at Tyr15 inactivates cdc2 and leads to mitosis delay,
while dephosphorylation of Tyr 15 promotes G2 to M phase transition. Aurone 5a induced
dephosphorylation of Tyr 15 and activated cdc2 (Figure 4.10), which could be explained
as a feedback rescue under aurone 5a treatment. Cdc2 can be inhibited by RO3306, a cellpermeable and selective ATP-competitive reversible inhibitor. Synergistic effects between
RO3306 and aurone 5a were observed (Figure 4.11), which provided molecular basis for
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combination usage of tubulin inhibitors and cyclin dependent kinase inhibitors for better
antineoplastic effects.
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Chapter 5 In vivo evaluation of the antineoplastic activity of aurones
Introduction
Tubulins are a well-known, valid drug target in oncology, and four small-molecule
binding sites in tubulins have been discovered to modulate the tubulin microtubule
dynamics72. Representative molecules that bind to the four unique sites in tubulins include
paclitaxel, Vinca alkaloids, colchicine, and laulimalide. Several tubulin inhibitors
including taxanes and vinorelbine gained FDA approval for cancer chemotherapy15.
Despite the fact that a large number of molecules that bind to the colchicine binding site
(CBS) were identified, there is no FDA approved tubulin inhibitors targeting the CBS15.
A major obstacle of tubulin inhibitors as chemotherapy is the neurological toxicity
induced by these agents73, and consequently, the dosing regimen for tubulin inhibitors that
target the CBS are crucial to avoid potential, unwanted neuropathy. Fortunately, our
leading compound, aurone 5a, possessed subnanomolar potency against cancer cells but
showed an IC50 in the micromolar range (1.3 ± 0.2 μM) against a normal human embryo
lung cell line HEL299, a finding that suggested aurone 5a was selectively toxic to cancer
cell lines rather than normal cell lines and was a suitable candidate for further in vivo
studies.
Although our studies focused on developing agents for the treatment of prostate
cancers, the prior report that aurones with 2-(coumarin-4-yl)methylene groups74 or 2(furan-2-yl)methylene groups75 displayed in vitro activity against human leukemia K562
cells prompted a study of myc-induced T-cell acute lymphoblastic leukemia (T-ALL) in a
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zebrafish model. Before testing aurone 5a in vivo, several leukemia cell lines were treated
with 5a to assure that 5a is effective for leukemia.

Results
Mouse xenograft model
The in vivo tumor inhibitory effect of aurone 5a using prostate cancer PC-3
xenografts in immune-defective nude mice. PC-3 cells were subcutaneously injected into
both flanks of nude mice. Two weeks after the inoculation, the mice were randomized to
two groups (n=5), treated with aurone 5a or control vehicle by intraperitoneal
administration for about 3 weeks and then sacrificed.

Compared to vehicle, the

administration of 5a at a low dose of 10 mg/kg/day showed significant, tumor-growth
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Figure 5.1: (A) Effects of aurone 5a on PC-3 tumor xenografts in nude mice (n=5)
at 10 mg/kg/day. (B) Effect on aurone 5a on body weights of the treated mice: * p <
0.05, t-test.

suppression (Figure 5.1A). Importantly, aurone 5a achieved tumor regression with no
apparent gross toxicity as reflected by minimal changes in mice weights (Figure 5.1B).
Effects on leukemia cells and T-ALL
In addition to the in vivo PC-3 xenograft study in mice, we sought to test these
aurones in a second species. Two prior reports indicated that aurones with 2-(coumarin-4yl)methylene groups or 2-(furan-2-yl)methylene groups displayed in vitro activity against
a leukemia cell line. Consequently, we tested various leukemia cell lines and found that
the IC50 values for aurone 5a were in the mid-nanomolar range (Table 6). The IC50 values
of two normal B-lymphoblast cells were much higher than the leukemia cell lines and
suggested a preferential toxicity of aurone 5a toward leukemia cells.
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Table 6. IC50 values of aurone 5a in leukemia cell line proliferation inhibition assays.

Cell Line

Cell Type

IC50 (nM)

CCRF-CEM
DND41
Jurkat
HBP-ALL
Loucy
Molt-4
Molt-16
RPMI8402
Nalm-16
REH

T-ALL
T-ALL
T-ALL
T-ALL
T-ALL
T-ALL
T-ALL
T-ALL
B-ALL
B-ALL
Normal BLymphoblast
Normal BLymphoblast

244
210
273
94
334
241
234
301
272
287

95% Confidence
Interval (nM)
197-301
116-379
226-344
51-173
285-391
114-402
218-250
248-364
248-291
252-326

1,253

429-3,658

1,379

372-2,490

NCI-BL2009
HCC1007-BL

Because these leukemia cell lines had various mutations, we tested the activity of
aurone 5a in vivo using a genetically well-defined, zebrafish myc-induced T-ALL leukemia
model76,77. The zebrafish (Danio rerio) is a vertebrate system that develops tumors similar
to those in humans and that provides a platform that is easy to manipulate for in vivo assays
even in large-scale screens. According to previous studies76,77, the zebrafish Rag2 promotor
controlling the myc-GFP transgene specifically targets gene expression to lymphoid cells.
The Rag2: myc-GFP transgene was micro-injected into wild-type zebrafish embryos at the
one-cell development stage, and a small fraction of injected embryos developed c-myc
induced leukemia. GFP-labeled leukemia cells in zebrafish were treated with either DMSO
(Figure 5.2A at day 0 and Figure 5.2D at day 5); aurone 5a in DMSO (Figure 5.2B at day
0 and Figure 5.2E at day 5); or aurone 5r in DMSO (Figure 5.2C at day 0 and Figure 5.2F
at day 5). Since aurone 5a had auto-fluorescence that interfered with visualizing the loss
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of the GFP-labeled leukemia cells (Figure 5.2E), we selected aurone 5r that lacked this
auto-fluorescence and clearly displayed the loss of the GFP-labeled leukemia cells (Figure
5.2F). Aurone 5a and 5r significantly blocked the progression of T-ALL in zebrafish
(Figure 5.2D versus Figure 5.2F, Figure 5.2G).

Figure 5.2: Aurones 5a and 5r inhibited myc-induce T-ALL in a zebrafish model. (A
and D) Treatment of GFP-labeled thymic lymphoma cells with DMSO alone at day 0
and day 5, respectively. (B and E) Treatment of GFP-labeled thymic lymphoma cells
with aurone 5a in DMSO at day 0 and day 5, respectively. (C and F) Treatment of GFPlabeled thymic lymphoma cells with aurone 5r at day 0 and day 5, respectively. (G)
Percent change in fluorescence (i.e., number of GFP-labeled thymic lymphoma cells)
as a function of time from administration of DMSO alone to the administration of
aurone 5r in each zebrafish (n=8).
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Discussion
The in vitro studies led to the identification of inhibiting tubulin polymerization as
the mechanism of action of aurone 5a and consequently the in vivo tumor inhibitory effects
of aurone 5a using prostate cancer PC-3 xenografts in immune-defective nude mice was
evaluated. Compared to vehicle, the administration of aurone 5a at a low dose of 10
mg/kg/day for 18 days showed significant, tumor-growth suppression (Figure 5.1A).
Importantly, aurone 5a achieved tumor regression with no apparent gross toxicity as
reflected by minimal changes in mice weights (Figure 5.1B).
In addition to the in vivo PC-3 xenograft study in mice, we validated the in vivo
anti-tumor efforts of these aurones in a second species. Because aurone 5a showed
nanomolar potency on several leukemia cell lines, we used a zebrafish T-ALL model to
test these aurones. The zebrafish (Danio rerio) is a vertebrate system that develops tumors
similar to those in humans and that provides a platform that is easy to manipulate for in
vivo assays even in large-scale screens. No gross toxicity on zebrafish but significant
inhibition of myc-induced T-ALL in vivo was observed (Figure 5.2). The zebrafish mycinduced T-ALL model could be an important in vivo tool to screen and characterize future
aurone analogs. Overall, these in vivo data confirmed anti-tumor efficacy of aurones 5a
and 5r in vivo, suggesting 5a and 5r could be potential chemotherapy drug candidates.
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Chapter 6 Conclusions and future directions
Conclusions
Nature is the best chemist in terms of manipulating enzymes to make molecules
necessary to sustain life processes. This evolutionary outcome provides an abundant
reservoir of diverse chemical scaffolds that serve as departure points for drug discovery. A
survey looking at natural products as sources of new drugs from 1981 to 2014 found that
over 60% of current drugs are related to natural compounds78. This project started from a
less-distributed and less-studied flavone possessing the aurone scaffold30, and we
successfully identified potential drug candidates for cancer chemotherapy.
To generate these new aurone analogs, modifications were made on both C-6 and
C-2 positions of benzofuran-3(2H)-one. Cell proliferation assays using PC-3 cells were
carried out to determine the relative proliferation inhibition for new aurones compared to
the vehicle control DMSO. Heterocyclic-substituted phenylmethylene groups or
heteroarylmethylene groups were attached at C-2, and the C-6 position was modified with
halogenated benzyls or cyanomethyl. Two candidates, (Z)-2-((2-((1-ethyl-5-methoxy-1Hindol-3-yl)methylene)-3-oxo-2,3-dihydrobenzofuran-6-yl)oxy)acetonitrile (5a) and (Z)-6((2,6-dichlorobenzyl)oxy)-2-(pyridin-4-ylmethylene)benzofuran-3(2H)-one (5r), showed
nanomolar potencies towards a panel of cancer cell lines.
One of the possible reasons why most published aurone analogs lack a clear
mechanism of action is low potency. With the potent aurones 5a and 5r in hand, the
combination of NCI-60 cell line panel assay and the NCI COMPARE analysis suggested
that the biological target of aurone 5a was tubulin. In vivo and in vitro tubulin
polymerization assays confirmed that aurone 5a inhibited tubulin polymerization. Because
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microtubules are key components of cell cytoskeleton and mitotic spindle, aurone 5a
treatment resulted in abnormal cell morphology and cell cycle arrest at G2/M phases. These
results further confirmed that tubulin was the biological target of aurone 5a.
The colchicine-binding site resides at the interfaces of αβ tubulins and binds a set
of structurally diverse molecules. Molecular docking of aurone 5a, a less active aurone 4d,
and a well-known CBS binder colchicine to the CBS revealed key interactions between
aurone 5a and αβ tubulins. To confirm the binding site, a competitive binding assay in
which aurone 5a with increasing concentrations competed with fixed amount of colchicine
for binding to the CBS was performed. Aurone 5a resulted in decreased binding between
tubulins and colchicine, showing that aurone 5a is a CBS binder.
One interesting finding during the course of target identification was the synergistic
effects between aurone 5a and Cdk1 inhibitor RO3306. In cell cycle, the G2-to-M phase
transition is controlled by cdc2 (cdk1). Cdc2 is tightly regulated by cyclin association and
phosphorylation of Tyr 15 of cdc2. Phosphorylation of cdc2 at Tyr15 inactivates cdc2 and
leads to mitosis delay, while dephosphorylation of Tyr 15 promotes G2 to M phase
transition. Mechanistically, since aurone 5a arrested cell cycle to G2/M, it’s reasonable for
cancer cells to dephosphorylate cdc2 at Tyr15 to push G2 to M phase transition as a
feedback rescue upon aurone 5a treatment. RO3306 inhibits cdc2 and the feedback rescue,
thus showing synergistic effects with aurone 5a.
The in vivo anti-tumor effects were confirmed in PC-3 mouse xenograft model and
leukemia T-ALL zebrafish model. Compared to vehicle, the administration of aurone 5a at
10 mg/kg/day showed significant tumor suppression. Importantly, aurone 5a achieved
tumor regression with no apparent gross toxicity as reflected by minimal changes in mice
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weights. Because aurone 5a possesses auto-fluorescence, the equally potent aurone 5r was
used in the zebrafish study and showed significant tumor growth inhibition.
Finally, aurone 5a was selectively toxic for cancer cells, and was not a substrate of
the hERG K+ channel and the P-glycoprotein that causing drug resistance. Considering that
so far no colchicine-site binders have been approved by the FDA, aurone 5a with strong
potency, clear mechanism of action and in vivo anti-tumor efficacy could be a potential
novel chemotherapy drug candidate as a colchicine-site binder.

Future directions
The pharmacokinetics of our aurones requires exploration. Bioavailability of the
current leading aurone analogs is unknown. Determining the half-life and metabolites of
aurones in vivo is a necessary next step in their potential development. How aurones are
excreted from the body warrants further examination.
The solubility of current leading candidates requires further improvement and will
probably require the synthesis of additional aurone analogs or the development of drug
formulations such liposomes and nanoparticles.
Although molecular docking and competitive binding assay show that the leading
two aurone analogs bind to the colchicine binding site of tubulins, how aurones and this
binding pocket interact with each other is unknown. Co-crystallizing aurones and tubulins
could potentially answer this question and allows the identification of critical amino acids
residing the binding pocket that interact with aurones. This knowledge would provide
information for rational design of next generation aurone analogs with improved potency
and solubility.
88

Finally, while the drug combination with RO3306 is effective in tumor cell lines,
it will be necessary to evaluate this combination in vivo. There are other FDA-approved
cell cycle inhibitors such as Palbociclib (PD-0332991) (inhibitor of CDK4 and CDK6). It’s
interesting to test how these FDA-approved cell cycle inhibitors affect the activity of
leading aurone candidates in vivo.
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APPENDIX A: Abbreviations
CBS - colchicine binding site
CDK - cyclin dependent kinase
CRISPR - clustered regularly interspaced short palindromic repeats
DAPI - 4′, 6-diamidino-2-phenylindole
DCM – dichloromethane
DMF - N,N-dimethylformamide
DMSO - dimethyl sulfoxide
EDC - N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide
EDTA - Ethylenediaminetetraacetic acid
EGFR - epidermal growth factor receptor
EGTA - ethylene glycol-bis(β-aminoethyl ether)
FDA - Food and Drug Administration
GDP - Guanosine diphosphate
GFP - green fluorescence protein
GTP - Guanosine triphosphate
HBSS - Hank’s balanced salt solution
HESI - heated electrospray ionization
LC-MS/MS - liquid chromatography electrospray ionization tandem mass spectrometry
NCI - National Cancer Institute
NSCLC - Non-Small Cell Lung Cancer
PBS - phosphate-buffered saline
PI - propidium iodide
PIPES - piperazine-N,N′-bis(2-ethanesulfonic acid)
PMSF - phenylmethylsulfonyl fluoride
SDS-PAGE - sodium dodecyl sulfate polyacrylamide gel electrophoresis
siRNA - small interfering RNA
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T-ALL - T-cell acute lymphoblastic leukemia
TKI - tyrosine kinase inhibitors
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APPENDIX B: Collaborations

Several of my colleagues made contributions to this aurone project. Liliia M. Kril
synthesized compounds 3a-f. Mykhaylo S. Frasinyuk synthesized 4a-l and 5d-5r. Vitaliy
M. Sviripa characterized compounds 3a-f, 4a-l and 5d-5r. Agripina Deaciuc performed
hERG assay. Jing Chen run LC-MS/MS and Elizabeth Hausman did zebrafish study. I
appreciate their input and welcomed their authorship in our recent publication in Scientific
Reports (2019).
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